<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2312200356
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2011
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEROXAT CR 25MG TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PAROXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        82.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Bora Pharmaceutical Services Inc" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Bora Pharmaceutical Services Inc
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>called SSRIs (<em>selective serotonin reuptake inhibitors</em>). In adults aged 18 years and over Seroxat CR is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; major depressive disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a severe form of premenstrual syndrome (<em>premenstrual dysphoric disorder</em>), symptoms include depression, severe mood changes, irritability.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; panic attacks, including those caused by a fear of open spaces (<em>agoraphobia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anxiety caused by situations such as socialising or performance.</p><p>These conditions can occur when the amount of a substance called serotonin in the brain is reduced. Paroxetine works by increasing serotonin levels in the brain.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take Seroxat CR </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic </strong>(<em>hypersensitive</em>) to paroxetine or any other ingredients of Seroxat CR (listed in Section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken (within the last two weeks) <strong>medicines for depression</strong> called <strong>monoamine oxidase inhibitors (MAOIs)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken (within the last two weeks) an <strong>antibiotic</strong> medicine called <strong>linezolid</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking or have recently taken (within the last two weeks) a medicine called methylthioninium chloride<strong> (methylene blue)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking <strong>medicines called thioridazine or pimozide</strong> (usually used to treat schizophrenia)</p><p>&nbsp;</p><p>&Uacute; If you think any of these apply to you, <strong>don&rsquo;t take Seroxat CR</strong> until you have checked with your doctor.</p><p><strong>Take special care with Seroxat CR </strong></p><p><strong>Seroxat CR is not recommended for people aged under 18.</strong> The effectiveness of Seroxat CR has not been demonstrated in this age group. Medicines used to treat depression and other mental health problems may increase the risk of suicidal thoughts and behaviour in children and adolescents aged under 18 years. There is no information on the long-term safety of Seroxat CR in this age group.</p><p><strong>Before you take Seroxat CR your doctor needs to know:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have taken <strong>medicines for depression called MAOIs</strong> and the date you stopped taking them</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have taken an antibiotic called <strong>linezolid </strong>and the date you stopped it</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are taking <strong>tamoxifen</strong> (used to treat or prevent breast cancer)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>episodes of hyperactivity, elation and irritability</strong> (<em>mania</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>periods of mania alternating with periods of depression</strong> (<em>bipolar mood disorder</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>kidney or liver disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>heart disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your<strong> heart tracing (electrocardiogram/ECG) has an abnormality known as prolonged QT interval </strong>or you are taking medicines that may affect the QT interval in the ECG</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>epilepsy</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from <strong>glaucoma</strong> (a condition caused by raised pressure in the eye)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of <strong>bleeding problems</strong>, or are taking medicines that increase your risk of bleeding</p><p>&nbsp;</p><p>&Uacute; <strong>Check with your doctor</strong> if you think any of these may apply to you. Your doctor will decide whether Seroxat CR is suitable for you, or if you need extra check-ups.</p><p>&nbsp;</p><p><strong>Thoughts of suicide or worsening of your condition </strong></p><p>If you are depressed, you may sometimes have suicidal thoughts or thoughts of harming yourself. Since medicines like Seroxat CR take time to work (usually about 2 weeks, but sometimes longer), suicidal thoughts or thoughts of harming yourself may continue or increase, particularly when you start taking Seroxat CR.</p><p>You may be more likely to think like this if you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are a young adult</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have previously had thoughts of this nature</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have recently had a change in dose</p><p>If you have distressing thoughts or experiences, or if you notice that you feel worse or develop new symptoms while you&rsquo;re taking Seroxat CR:</p><p>&Uacute;&nbsp; <strong>Contact your doctor or go to a hospital straight away.</strong></p><p><strong>You may find it helpful to tell a relative or close friend </strong>that you are depressed, and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.</p><p><strong>Conditions you need to look out for </strong></p><p>Medicines like Seroxat CR used to treat mental health problems can on rare occasions cause serious conditions called Serotonin Syndrome and Neuroleptic Malignant Syndrome. You must look out for certain symptoms while you are taking Seroxat CR, to reduce the risk of any problems. See &lsquo;<em>Conditions you need to look out for</em>&rsquo; <em>in <strong>Section 4</strong></em>.</p><p><strong>Akathisia</strong></p><p>Medicines used to treat some mental health problems can cause a feeling of inner restlessness and the urge to move (akathisia). This is a rare side effect of Seroxat CR, and is most likely to occur in the first few weeks of treatment.</p><p>&Uacute;&nbsp; <strong>Tell your doctor as soon as possible </strong>if you get these symptoms.</p><p><strong>Sexual Dysfunction</strong></p><p>Medicines like Seroxat CR (so called SSRIs) may cause symptoms of sexual dysfunction (see <strong>Section 4</strong>). In some cases, these symptoms have continued after stopping treatment.</p><p><strong>Bone fracture </strong></p><p>There is an increased risk of bone fracture (breaking a bone) in people taking medicines like Seroxat CR. This risk is greatest during the early stages of treatment.</p><p><strong>Alcoholic drink and Seroxat CR </strong></p><p>It is recommended that you don&rsquo;t drink alcohol while you&rsquo;re taking Seroxat CR.</p><p><strong>Other medicines and Seroxat CR </strong></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes herbal medicines and other medicines you bought without a prescription.</p><p>Some medicines must not be taken with Seroxat CR, see &lsquo;<strong>Don&rsquo;t take Seroxat CR</strong>&rsquo; at the beginning of <strong>Section 2</strong>.</p><p>Taking Seroxat CR with medicines which may raise serotonin levels in the brain, can increase your risk of side effects (see &lsquo;<em>Conditions to look out for</em>&rsquo; in <strong>Section 4</strong>). These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; triptans (used to treat <strong>migraine</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tramadol (used to treat <strong>pain</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tryptophan or SSRIs (used to treat <strong>depression</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s Wort (a herbal remedy used to treat <strong>depression</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; lithium (used to treat <strong>some mental health problems</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fentanyl (used in <strong>anaesthesia </strong>or to treat <strong>chronic pain</strong>)</p><p>&nbsp;</p><p>&Uacute;&nbsp; <strong>Tell a doctor or pharmacist</strong> if you are taking any of these. You should be closely monitored while you are taking them with Seroxat CR.</p><p>Some medicines can affect how Seroxat CR works. Seroxat CR can also affect how some other medicines work. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, phenobarbital and phenytoin which are usually used to treat <strong>fits </strong>(seizures or epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; mivacurium and suxamethonium (used in <strong>anaesthesia</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin (used to treat <strong>tuberculosis</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fosamprenavir and ritonavir (used to treat <strong>HIV</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; procyclidine (used to treat <strong>Parkinson&rsquo;s disease</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; amitriptyline, nortriptyline, imipramine and desipramine (used to treat <strong>depression</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; perphenazine and risperidone (used to treat <strong>some mental health problems</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; atomoxetine (used to treat <strong>attention deficit hyperactivity disorder, ADHD</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; propafenone and flecainide (used to treat <strong>an irregular heart beat</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; metoprolol (used to treat <strong>high blood pressure</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tamoxifen (used to treat or prevent <strong>breast cancer or fertility problems</strong>).</p><p>&nbsp;</p><p>&Uacute;&nbsp; <strong>Tell a doctor or pharmacist</strong> if you are taking any of these. Your doctor may decide to adjust your dose.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Seroxat CR is not usually recommended for use during pregnancy. If you are <strong>pregnant</strong> or <strong>think you could be</strong>, or if you are <strong>planning to become pregnant</strong>, <strong>speak to your doctor immediately</strong>. <strong>Your doctor</strong> will consider the benefit to you and the risk to your baby of taking Seroxat CR while you&#39;re pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some studies have reported an increase in the risk of birth defects, particularly heart defects, in babies whose mothers were taking Seroxat CR in the first few months of pregnancy. These studies found that about 1 in 50 babies (2%) whose mothers received Seroxat CR in early pregnancy had a heart defect, compared with the normal rate of 1 in 100 babies (1%) seen in the general population</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A birth complication called persistent pulmonary hypertension of the new-born (PPHN) has been seen in babies whose mothers were taking antidepressants including Seroxat CR during pregnancy. In PPHN, the blood pressure in the blood vessels between the baby&#39;s heart and the lungs is too high. The risk of PPHN occurring in babies whose mothers used antidepressants like Seroxat CR late in pregnancy was reported to be 4 to 5 times higher than the risk of PPHN seen in the general population which is about 1 to 2 cases per 1000 pregnancies</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of premature births for mothers taking Seroxat CR during pregnancy. It is not known if these are due to the use of Seroxat CR.&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you take Seroxat CR near the end of your pregnancy there may be an increased risk of excessive vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking Seroxat CR so they can advise you.</p><p>If Seroxat CR is used until delivery, the following symptoms have been reported in babies immediately or within the first 24 hours after birth. Again, it is not known if these symptoms are due to the use of Seroxat CR.&nbsp; The symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; trouble with breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a blue-ish skin or being too hot or cold</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting or not feeding properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being very tired, not able to sleep or constant crying</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiff or floppy muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors, jitters or fits</p><p>&nbsp;</p><p>&Uacute;&nbsp; If your baby has any of these symptoms when it is born, or you are concerned about your baby&rsquo;s health, <strong>contact your doctor or midwife for advice</strong>.</p><p>The ingredients in Seroxat CR can pass into breast milk. <strong>If you are breast-feeding, you must check with your doctor </strong>before you take Seroxat CR.</p><p>Medicines like Seroxat CR may affect your sperm. Fertility may be reduced in some men during treatment with Seroxat CR.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Seroxat CR can make you feel dizzy or confused and can affect your eyesight.</p><p>&Uacute;&nbsp; <strong>Don&rsquo;t drive or use machines</strong> if you get side effects such as these.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take Seroxat CR exactly as your doctor has told you to</strong>. Check with your doctor or pharmacist if you&#39;re not sure.</p><p><strong>How much to take </strong></p><p><strong>The starting dose </strong>of Seroxat CR depends on your illness. It is usually 12.5 mg or 25 mg once a day. Your doctor may gradually increase your dose to help control your symptoms.</p><p>If you are over 65, or have liver or kidney problems, the maximum dose may be reduced.</p><p><strong>How to take </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Swallow your Seroxat CR tablets whole with some water. Don&rsquo;t chew, crush or split the tablets </strong>&mdash; if you do, there is a danger you could overdose, because the medicine may be released into your body too quickly.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Seroxat CR in the morning.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Seroxat CR with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant caregivers should avoid exposure to <em>Seroxat CR </em>tablets.</p><p><strong>How long to take it for </strong></p><p>The duration of treatment will depend on your illness. Whilst people usually feel some improvement within two weeks or so, it can take longer for the medicine to have its full effect.</p><p>Even after you start to feel better, it is important to keep taking Seroxat CR for as long as your doctor recommends to help prevent symptoms from returning. This can be several months after recovery from depression and may even be longer for panic disorder.</p><p><strong>If you forget to take Seroxat CR </strong></p><p><strong>Don&#39;t take an extra dose</strong> to make up for a missed one. Just take your next dose at the usual time.</p><p>&Uacute;&nbsp; <strong>If you are not sure what to do</strong>, ask your doctor or pharmacist.</p><p><strong>If you take too much Seroxat CR </strong></p><p>If you take too much Seroxat CR, you are more likely to get side effects (see <strong>Section 4</strong>). Taking too much Seroxat CR may also cause blood pressure changes, uncontrollable muscle contractions, anxiety, a high temperature, and a fast heartbeat.</p><p>&Uacute;&nbsp; If you take too much Seroxat CR, <strong>contact your doctor or pharmacist for advice</strong>. If possible, show them the Seroxat CR pack.</p><p><strong>Don&rsquo;t stop Seroxat CR without advice </strong></p><p><strong>Don&rsquo;t stop taking Seroxat CR without talking to your doctor first.</strong> Your dose needs to be reduced gradually, otherwise you may get side effects (see &lsquo;<em>Symptoms seen when Seroxat CR is stopped</em>&rsquo; at the end of <strong>Section 4</strong>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Seroxat CR can cause side effects, but not everybody gets them.</p><p><strong>Conditions to look out for</strong></p><p>Severe allergic reactions. These are very rare in people taking Seroxat CR. Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; raised and itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; collapse or loss of consciousness</p><p>&nbsp;</p><p>&Uacute;&nbsp; <strong>Contact a doctor immediately if you get these symptoms. Stop taking Seroxat CR.</strong></p><p><strong>Serotonin Syndrome and Neuroleptic Malignant syndrome</strong></p><p>Medicines that may increase serotonin activity in the brain can cause a condition called Serotonin Syndrome. This is a very rare side effect of Seroxat CR. Taking Seroxat CR with other medicines which may also raise serotonin activity in the brain, can increase the risk of this serious side effect (see &lsquo;<em>Other medicines and Seroxat CR</em>&rsquo; in <strong>Section 2</strong>). Another condition called Neuroleptic Malignant Syndrome is a rare side effect of medicines used to treat mental health problems.</p><p>The symptoms of both Serotonin Syndrome and Neuroleptic Malignant Syndrome are similar. Usually more than one of the following symptoms will occur:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; sudden uncontrollable jerky movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; muscle stiffness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sitting still</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling very agitated or irritable</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling hot or sweaty</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increase in heart rate</p><p>The severity can increase, leading to loss of consciousness.</p><p>&Uacute;&nbsp; <strong>Contact your doctor urgently </strong>if you get these symptoms.</p><p><strong>Akathisia</strong></p><p>Medicines used to treat some mental health problems can cause a feeling of inner restlessness and the urge to move (<em>akathisia</em>). This is a rare side effect of Seroxat CR, and is most likely to occur in the first few weeks of treatment.</p><p>&Uacute;&nbsp; <strong>Tell your doctor as soon as possible </strong>if you get these symptoms.</p><p><strong>Very common side effects </strong></p><p>These may affect <strong>more than 1 in 10</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a change in sex drive or sexual function.</p><p><strong>Common side effects </strong></p><p>These may affect<strong> up to 1 in 10</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; difficulty in sleeping (insomnia) or feeling drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling agitated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; yawning</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormal dreams (including nightmares)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p><strong>Common side effects that may show up in blood tests:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; increase in cholesterol.</p><p><strong>Uncommon side effects </strong></p><p>These may affect<strong> up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; bruising or unusual bleeding mainly of the skin and moist areas such as the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; seeing or hearing things that are not really there (<em>hallucinations</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; involuntary muscle movements of the face, twisting movements of the body, arms and legs, tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; dilated pupils</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a faster than normal heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (may cause dizziness, light-headedness or fainting when standing up from a sitting or lying position)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; skin rashes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; unable to pass urine (<em>urinary retention</em>) or loss of control of the bladder (<em>urinary incontinence</em>)</p><p><strong>Rare side effects </strong></p><p>These may affect <strong>up to 1 in 1,000 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of restlessness and difficulty sitting or standing still (<em>akathisia</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; episodes of hyperactivity, elation and irritability (<em>mania</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; fits (<em>seizures</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; irresistible urge to move the legs (<em>Restless Legs Syndrome</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; abnormal secretion of breast milk in men and women</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; menstrual period disorders (including heavy periods, bleeding between periods and absence of periods)</p><p><strong>Rare side effects that may show up in blood tests:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in sodium levels in the blood (especially in the elderly)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in substances (<em>enzymes</em>) from the liver</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in a hormone called prolactin</p><p><strong>Very rare side effects </strong></p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serotonin Syndrome</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surround by a paler area, with a dark ring around the edge) called <em>erythema multiforme</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (<em>Stevens-Johnson syndrome</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and skin peeling on much of the body surface (<em>toxic epidermal necrolysis</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased amounts of a hormone (ADH) that causes water retention</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glaucoma (a condition caused by raised pressure in the eye)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the digestive system (passing blood in the stools or black stools)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>), sometimes causing yellowing of the skin and the whites of the eyes (<em>jaundice</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of the skin to sunlight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of hands, ankles or feet</p><p><strong>Very rare side effects that may show up in blood tests:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; decrease in number of blood platelets (cells that help blood to clot)</p><p><strong>If you get side effects </strong></p><p>&Uacute;&nbsp; <strong>Tell your doctor or pharmacist </strong>if any of the side effects listed becomes<strong> severe or troublesome, </strong>or if you notice any side effects not listed in this leaflet.</p><p><strong>Symptoms seen when Seroxat CR is stopped</strong></p><p>Stopping medicines used for treating mental health problems often causes unwanted symptoms. The symptoms are more likely to occur in the first few days of stopping treatment and usually go away within a few weeks.</p><p>If you need to stop taking Seroxat CR, your doctor may reduce your dose gradually. This should help to reduce any effects and their severity.</p><p><strong>Common symptoms seen when Seroxat CR is stopped: </strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feelings like pins and needles, electric shock sensations and persistent noise in the ears (<em>tinnitus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleep disturbances including intense dreams</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p><strong>Uncommon symptoms seen when Seroxat CR is stopped: </strong></p><p>These may affect <strong>up to 1 in 100 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling restless or agitated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremors</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&nbsp;</p><p>&Uacute;&nbsp; <strong>Talk to your doctor </strong>if these symptoms become<strong> severe or troublesome.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep out of the reach and sight of children.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Seroxat after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; store SEROXAT CR below 25 &deg;C. Store it in its original packaging in dry place.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking SEROXAT CR, it is important to return any remnants which are left over to your pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have any unwanted SEROXAT CR tablets, don&rsquo;t dispose of them in your waste water or household rubbish. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transport and store medicine in the original container or blister.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What SEROXAT CR contains </strong></p><p>The active substance is paroxetine as paroxetine hydrochloride hemihydrate</p><p>SEROXAT CR tablets come in different strengths.</p><p>&nbsp;</p><p>Each tablet contains either:</p><p>12.5 mg or 25 mg paroxetine.</p><p>&nbsp;</p><p>The other ingredients are:</p><p>Hypromellose; Povidone; Lactose Monohydrate; Magnesium Stearate; Colloidal silicon dioxide; Glyceryl behenate; Methacrylic Acid Copolymer Dispersion; Talc; Triethyl citrate, Opadry Yellow, YS-1-2007 (12.5 mg tablets), Opadry Pink, Y-1-1262 (25 mg tablets) and the following colourants: Yellow Ferric Oxide (12.5mg tablets) and Red Ferric Oxide (25 mg tablets).</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12.5 mg tablets: Yellow, with GSK engraved on one side and 12.5 on the other side.
25 mg tablets: Pink, with GSK engraved on one side and 25 on the other side.
SEROXAT CR tablets 12.5 mg: Foil blister packs or HDPE bottles with child-resistant closures
SEROXAT CR tablets 25 mg: Foil blister packs or HDPE bottles with child-resistant closures
Not All packs are marketed in every country. ‎
SEROXAT is a trademark owned by or licensed to the GSK group of companies.
©2024 GSK group of companies. All rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>Bora Pharmaceuticals Service Inc., Mississauga, Canada</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>&nbsp;</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p>GlaxoSmithKline - Head Office, Jeddah</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:roundrect id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_5"
 o:spid="_x0000_s1026" style='position:absolute;margin-left:0;margin-top:8.8pt;
 width:481.9pt;height:238.5pt;z-index:251663360;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:center;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' arcsize="10923f"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" strokeweight="2.5pt">
 <v:shadow color="#868686"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:6.0pt;margin-right:0in;margin-bottom:
    0in;margin-left:0in;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
    style='font-size:14.0pt;mso-bidi-font-size:12.0pt;mso-fareast-language:
    EN-US'>To report any side effect(s): <o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
    0in;margin-left:0in;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
    style='font-size:7.0pt;mso-bidi-font-size:6.0pt;mso-fareast-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:-.1pt;margin-bottom:
    0in;margin-left:0in;mso-list:skip'><b style='mso-bidi-font-weight:normal'><span
    style='mso-bidi-font-size:11.0pt;mso-fareast-language:EN-US'>Kingdom of
    Saudi Arabia<o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b
    style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
    mso-fareast-language:EN-US'>-National Pharmacovigilance centre (NPC) <o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
    12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'>Reporting Hotline: 19999 <o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span lang=FR
    style='mso-bidi-font-size:12.0pt;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol;mso-ansi-language:FR'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=FR
    style='mso-bidi-font-size:12.0pt;mso-fareast-font-family:Calibri;
    mso-ansi-language:FR'>E-mail : </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    lang=FR style='mso-bidi-font-size:11.0pt;color:blue;mso-ansi-language:FR;
    mso-fareast-language:EN-US'>npc.drug@sfda.gov.sa</span></a><span lang=FR
    style='mso-bidi-font-size:11.0pt;mso-ansi-language:FR;mso-fareast-language:
    EN-US'> </span><span lang=FR style='mso-bidi-font-size:12.0pt;mso-fareast-font-family:
    Calibri;mso-ansi-language:FR'><span style='mso-spacerun:yes'> </span><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
    12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'>Website: </span><a
    href="https://ade.sfda.gov.sa"><span lang=EN-US style='mso-bidi-font-size:
    11.0pt;color:blue;mso-ansi-language:EN-US;mso-fareast-language:EN-US'>https://ade.sfda.gov.sa</span></a><u><span
    lang=EN-US style='mso-bidi-font-size:11.0pt;color:blue;mso-ansi-language:
    EN-US;mso-fareast-language:EN-US'> </span></u><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><span
    style='font-size:8.0pt;mso-fareast-font-family:Calibri'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoNormal style='margin-bottom:0in;text-autospace:none'><b
    style='mso-bidi-font-weight:normal'><span style='mso-bidi-font-size:11.0pt;
    mso-fareast-language:EN-US'>-GlaxoSmithKline - Head Office, Jeddah <o:p></o:p></span></b></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
    12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'>Tel: +966-12-6536666 <o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
    12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'>Mobile: +966-56-904-9882 <o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt'><![if !supportLists]><span style='mso-bidi-font-size:11.0pt;
    font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol;mso-fareast-language:EN-US'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=LTR></span><span style='mso-bidi-font-size:11.0pt;mso-fareast-language:
    EN-US'>Email: <a name="_Hlk49089500"></a><a
    href="mailto:saudi.safety@gsk.com"><span style='mso-bookmark:_Hlk49089500'><span
    style='color:blue'>saudi.safety@gsk.com</span></span><span
    style='mso-bookmark:_Hlk49089500'></span></a><span
    style='mso-spacerun:yes'>  </span><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
    12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'>Website: </span><a
    href="https://gskpro.com/en-sa/"><span style='mso-bidi-font-size:11.0pt;
    color:blue;mso-fareast-language:EN-US'>https://gskpro.com/en-sa/</span></a><span
    lang=EN-US style='mso-bidi-font-size:11.0pt;mso-ansi-language:EN-US;
    mso-fareast-language:EN-US'><span style='mso-spacerun:yes'>   </span></span><span
    lang=EN-US style='font-size:14.0pt;mso-fareast-font-family:Calibri'><span
    style='mso-spacerun:yes'> </span></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'><o:p></o:p></span></p>
    <p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:
    0in;margin-left:.5in;text-indent:-.25in;mso-list:l1 level1 lfo2;tab-stops:
    28.35pt;text-autospace:none'><![if !supportLists]><span style='mso-bidi-font-size:
    12.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='mso-bidi-font-size:
    12.0pt;mso-fareast-font-family:Calibri'>P.O. Box 55850, Jeddah 21544, Saudi
    Arabia <o:p></o:p></span></p>
    <p class=MsoNormal><o:p>&nbsp;</o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="649" height="325" alt="Rectangle: Rounded Corners: 	To report any side effect(s): 
	
	Kingdom of Saudi Arabia
-National Pharmacovigilance centre (NPC) 
•	Reporting Hotline: 19999 
•	E-mail : npc.drug@sfda.gov.sa  
•	Website: https://ade.sfda.gov.sa 

-GlaxoSmithKline - Head Office, Jeddah 
•	Tel: +966-12-6536666 
•	Mobile: +966-56-904-9882 
•	Email: saudi.safety@gsk.com  
•	Website: https://gskpro.com/en-sa/    
•	P.O. Box 55850, Jeddah 21544, Saudi Arabia 

" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version number: GDS49 
Date of issue: 16 July 2024


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">المادة الفعالة في سيروكسات سي.آر. هي پاروكسيتين، التي تنتمي لمجموعة أدوية تسمى مثبطات امتصاص السيروتينين الاختيارية (SSRIs). وذلك للبالغين من سن 18 سنة فما فوق يستخدم سيروكسات سي.آر. في علاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الاكتئاب الحادة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة شديدة من متلازمة سابقة الحيض (<em>الاكتئاب المسبق للدورة الشهرية</em>)، أعراضه تشمل اكتئاب، تقلبات المزاج الحادة، الاضطراب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات هلع، تشمل التي تحدث بسبب الخوف من الأماكن المفتوحة (<em>رهاب الخلاء</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلق بسبب مواقف مثل التواصل أو الأداء الاجتماعي</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الحالات تحدث عندما تكون المادة التي تدعى سيروتينين مستوياتها منخفضة في المخ. پاروكسيتين يعمل على زيادة مستويات السيروتينين في المخ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستعمل سيروكسات سي.آر.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصاب بالحساسية (<em>الحساسية المفرطة</em>) للپاروكسيتين أو أي مواد أخرى في سيروكسات سي.آر. (المدرجة في الفقرة 6)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تتناول أو تناولت مؤخراً (خلال الأسبوعين الأخيرين) <strong>عقاقير لعلاج الاكتئاب</strong> تدعى <strong>مثبطات أوكسيديز أحادي الأمين (</strong><strong>MAOIs</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخراً (خلال الأسبوعين الأخيرين) عقار مضاد حيوي يدعى <strong>لينيزوليد</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أو تناولت مؤخراً (خلال الأسبوعين الأخيرين) عقار يدعى كلورايد ميثيل ثيونينيوم (<strong>ميثيلين أزرق</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول عقاقير تدعى ثيوريدازاين أو بيموزايد (عادة يستخدم لعلاج <strong>انفصام الشخصية</strong>)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; إذا كنت تعتقد أن أيا مما سبق ينطبق عليك، <strong>لا تستعمل سيروكسات سي.آر.</strong> حتى تتأكد من طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توخى الحذر الشديد عند استعمال سيروكسات سي.آر.</strong></p><p dir="RTL"><strong>لايوصى باستعمال سيروكسات سي.آر. للأشخاص في سن أقل من 18 سنة.</strong> فعالية سيروكسات سي.آر. لم تحدد في هذه الفئة العمرية. الأدوية التي تستخدم لعلاج الاكتئاب ومشاكل الصحة العقلية قد تزيد من خطر الأفكار الانتحارية والسلوك الانتحاري في الأطفال والمراهقين في سن أقل من 18 سنة. لاتوجد معلومات على المدى الطويل عن مأمونية سيروكسات سي .آر في هذه الفئة العمرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قبل أن تبدأ بتناول سيروكسات سي.آر. طبيبك يحتاج إلى أن يعرف: </strong></p><ul><li dir="RTL">إذا كنت تتناول <strong>عقاقير لعلاج الاكتئاب تدعى مثبطات أوكسيديز أحادي الأمين (</strong><strong>MAOIs</strong><strong>)</strong> وتاريخ توقفك عن تناولها</li><li dir="RTL">إذا كنت تتناول مضاد حيوي يسمى <strong>لينيزوليد</strong> وتاريخ توقفك عن تناوله</li><li dir="RTL">إذا كنتِ تتناولين <strong>تاموكسيفين</strong> (يستخدم لعلاج والوقاية من سرطان الثدي)</li><li dir="RTL">إذا سبق وأن أصبت <strong>بنوبات فرط النشاط</strong>، <strong>انتشاء واضطراب</strong> (<em>هوس</em>)</li><li dir="RTL">إذا سبق وأن أصبت <strong>بفترات من الهوس تتبادل مع فترات من الاكتئاب</strong> (<em>اضطراب المزاج ثنائي القطب</em>)</li><li dir="RTL">إذا كان لديك <strong>مرض في الكلى أو الكبد</strong></li><li dir="RTL">إذا كان لديك <strong>مرض في القلب</strong></li><li dir="RTL">إذا كان رسم القلب (<strong>مخطط كهربية القلب/</strong> <strong>ECG</strong>) به <strong>خلل يُعرف باسم الفاصل الزمني المطول</strong> <strong>(</strong><strong>prolonged QT interval</strong><strong>)</strong>، أو إذا كنت تتناول أدوية قد تؤثر على الفاصل الزمني في مخطط كهربية القلب</li><li dir="RTL">إذا كنت مصاب <strong>بالصرع</strong></li><li dir="RTL">إذا كنت مصاب<strong> بالماء الأزرق</strong> (حالة سببها ارتفاع ضغط دم العين)</li><li dir="RTL">إذا كان لديك تاريخ في <strong>مشاكل النزيف</strong>، أو كنت تتناول أدوية تزيد من مخاطر النزيف</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>تأكد من طبيبك</strong> إذا كنت تعتقد أن أياً مما سبق ينطبق عليك. طبيبك سيقرر إذا ما كان سيروكسات سي.آر. مناسبا لك، أو إذا كنت تحتاج لفحوصات إضافية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أفكار انتحارية أو تدهور حالتك</strong></p><p dir="RTL">إذا كنت مصابا بالاكتئاب، قد يكون لديك في بعض الأحيان أفكار انتحارية أو أفكار لإيذاء نفسك. أدوية مثل سيروكسات سي.آر. تتطلب وقتاً لكي تعمل (عادة أسبوعين لكن في بعض الأحيان أكثر)، الأفكار الإنتحارية أو أفكار إيذاء نفسك قد تستمر أو تزيد، خصوصاً عندما تبدأ باستخدام سيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يزداد تفكيرك بهذه الأشياء إذا كنت:</p><ul><li dir="RTL">إذا كنت شاب صغيراً</li><li dir="RTL">سبق وأن كان لديك أفكار من هذا النوع</li><li dir="RTL">قمت بتغيير الجرعة مؤخراً</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أفكار محزنة أو سبق وأن كان لديك هذه الأفكار، أو إذا لاحظت أنك تشعر بأنك أسوأ أو إذا تطورت لديك أعراض جديدة أثناء استعمالك لسيروكسات سي.آر.:</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong><strong>اتصل بطبيبك أو اذهب الى المستشفى على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قد تجد أنه من المفيد أن تخبر قريب أو صديق مقرب</strong> بأنك تعاني من الاكتئاب، واطلب منهم أن يقرأوا هذه النشرة. تستطيع أن تسألهم إذا كانوا يعتقدون أن اكتئابك أصبح أسوأ، أو إذا كانوا قلقين حول التغيرات في سلوكك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات تحتاج لأخذ الحذر فيها:</strong></p><p dir="RTL">عقاقير مثل سيروكسات سي.آر. تستخدم لعلاج حالات الاضطرابات العقلية تستطيع في مناسبات نادرة أن تسبب حالات خطيرة تسمى متلازمة سيروتينين والمتلازمة الخبيثة للعقار المضاد للذهان. عليك الحذر من بعض الأعراض المعينة أثناء استعمالك لسيروكسات سي.آر.، للتقليل من خطر حدوث أي مشاكل. انظر &quot;<em>حالات تحتاج للحذر منها&quot;</em> في <strong>الفقرة 4</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التململ</strong></p><p dir="RTL">العقاقير التي تستخدم لعلاج بعض المشاكل العقلية قد تسبب شعور داخلي بعدم الراحة والحاجة الشديدة للحركة (التململ). هذا عرض جانبي نادر الحدوث مع سيروكسات سي.آر.، وغالبا ما يحدث في الأسابيع الأولى القليلة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>أخبر طبيبك بأقرب فرصة</strong> إذا كان لديك أي من هذه الأعراض.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>العجز الجنسي</strong></p><p dir="RTL">قد تسبب بعض الأدوية مثل سيروكسات (ما يسمى بمثبطات إعادة امتصاص السيروتونين الانتقائية) في أعراض الضعف الجنسي (انظر <strong>القسم 4</strong>). استمرت هذه الأعراض بعد توقف العلاج في بعض الحالات.</p><p dir="RTL"><strong>تحطم العظام</strong></p><p dir="RTL">هناك خطر متزايد لتحطم العظام (كسر في العظم) في الأشخاص الذين يتناولون عقاقير مثل سيروكسات سي.آر.، يكون الخطر أكبر في المراحل المبكرة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شرب الكحول وسيروكسات سي.آر.</strong></p><p dir="RTL">ينصح بعدم شرب الكحول خلال فترة استعمالك للسيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وسيروكسات سي.آر.</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تستعمل أي أدوية أخرى</strong>. إذا استعملت أي عقاقير مؤخراً، أو إذا بدأت باستعمال عقاقير جديدة. هذا يشمل العقاقير العشبية والعقاقير الأخرى التي تشتريها بدون وصفة طبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تؤخذ بعض العقاقير مع سيروكسات سي.آر.، انظر<strong> &rsquo;</strong> <strong>لا تستعمل سيروكسات سي.آر.&lsquo;</strong> في بداية <strong>الفقرة 2</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">استعمال سيروكسات سي.آر. قد يرفع مستويات السيروتنين في المخ، يزيد من خطر حدوث الأعراض الجانبية (انظر<em>&rsquo;حالات يجب الحذر منها&lsquo;</em> في <strong>الفقرة 4</strong>). هذه تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تربتانات (تستخدم في علاج <strong>الشقيقة</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترامادول (يستخدم في علاج <strong>الألم</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريبتوفان أو SSRIs (يستخدم في علاج <strong>الاكتئاب</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عشبة القديس جون (عقار عشبي يستخدم لعلاج <strong>الاكتئاب</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليثيوم (يستخدم لعلاج <strong>بعض الاضطرابات العقلية</strong>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فنتانيل ( يستخدم في <strong>التخدير</strong> أو لعلاج <strong>الألم المزمن</strong>)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>أخبر الطبيب أو الصيدلي</strong> إذا كنت تستعمل أياً من هذه. يجب أن تكون تحت المراقبة عن كثب أثناء استعمالك لسيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعض العقاقير قد تؤثر على كيفية عمل سيروكسات سي.آر.، أيضا قد يؤثر سيروكسات سي.آر. على كيفية عمل العقاقير الأخرى. هذه تشمل:</p><ul><li dir="RTL">كاربامازيبين، فينوباربيتال وفينيتوين الذين يستخدمون في العادة لعلاج <strong>النوبات</strong> (الخلجان أو الصرع(</li><li dir="RTL">مياڤكوريم وسوكساميثونيوم (يستخدمان في <strong>التخدير</strong>(</li><li dir="RTL">ريفامبيسين (يستخدم في علاج <strong>السل</strong>(</li><li dir="RTL">فوسامبريناڤير وريتوناڤير (يستخدم في علاج ا<strong>لإيدز</strong>(</li><li dir="RTL">بروسيكلايدين (يستخدم في علاج <strong>مرض باركنسون</strong>(</li><li dir="RTL">أميتريبتيلين، نورتريبتيلين، إيميبرامين وديسيبرامين (يستخدم في علاج <strong>الإكتئاب</strong>(</li><li dir="RTL">بيرفينازين وريسبيريدون (يستخدم في علاج <strong>بعض المشاكل العقلية</strong>(</li><li dir="RTL">أتوموكسيتين (يستخدم في علاج <strong>نقص الانتباه المصاحب لاضطراب فرط الحركة، </strong><strong>ADHD</strong>)</li><li dir="RTL">بروبافينون وفليكاينيد (يستخدم في علاج <strong>عدم انتظام ضربات القلب</strong>(</li><li dir="RTL">ميتوبرولول (يستخدم في علاج <strong>ضغط الدم المرتفع</strong>(</li><li dir="RTL">تاموكسيفين (يستخدم في علاج <strong>سرطان الثدي أو مشاكل الخصوبة</strong>(</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong><strong>أخبر الطبيب أو الصيدلي إذا </strong>كنت تستعمل أياً منها. قد يقرر طبيبك تعديل جرعتك<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا ينصح باستعمال سيروكسات سي.آر. أثناء الحمل. إذا كنتِ <strong>حامل</strong>، أو <strong>تعتقدين أنك حامل</strong>، أو <strong>تخططين للحمل</strong>، <strong>تحدثي إلى طبيبك على الفور</strong>. <strong>طبيبك</strong> سوف يقيّم المنافع والمضار لطفلك عند استعمالك سيروكسات سي.آر. أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الدراسات تشير إلى زيادة مخاطر حدوث تشوهات الولادة، خصوصاً خلل في القلب، في الأطفال الذين كانت أمهاتهم يستعملن سيروكسات سي.آر. في الأشهر القليلة الأولى من الحمل. هذه الدراسات وجدت أن حوالي طفل واحد من 50 طفل (2٪) من الذين كانت أمهاتهم يستعملن سيروكسات سي.آر. في المرحلة المبكرة من الحمل أصيبوا بخلل في القلب، بالمقارنة مع المعدل الطبيعي طفل واحد من كل 100 (1٪) في المجتمع بشكل عام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعقيدات الولادة التي تسمى ارتفاع الضغط الرئوي المتواصل للأطفال حديثي الولادة (PPHN) لوحظت في الأطفال الذين كانت أمهاتهم يستعملن عقاقير مضادة للاكتئاب بما فيها سيروكسات سي.آر. أثناء الحمل. في حالةPPHN ، يكون ضغط الدم مرتفعاً جداً في الأوعية الدموية بين قلب الطفل ورئته. تم تسجيل تضاعف خطر الإصابة PPHN &nbsp;في الأطفال الذين كانت أمهاتهم يستعملن عقاقير مضادة للاكتئاب مثل سيروكسات سي.آر. في المرحلة المتأخرة للحمل من 4 إلى 5 مرات أكثر من حدوثه في المجتمع بشكل عام والذي يكون معدل الإصابة به 1 إلى 2 حالة لكل 1000 حالة حمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تم تسجيل حالات لولادات مبكرة للأمهات يستعملن سيروكسات سي.آر. أثناء الحمل. من غير المعلوم إذا كان هذا له صلة باستخدام سيروكسات سي.آر. أثناء الحمل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تناولتِ سيروكسات قرب نهاية الحمل قد يكون هناك خطر متزايد من حدوث نزيف مهبلي مفرط بعد الولادة بقليل، خاصةً إذا كان لديك تاريخ من الاضطرابات النزفية. يجب أن يكون طبيبك أو قابلتك على دراية أنك تتناولين سيروكسات سي.آر. حتى يتمكنوا من تقديم النصيحة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تم استعمال سيروكسات سي.آر. حتى الولادة، الأعراض التالية سجلت في الأطفال على الفور أو بعد 24 ساعة من الولادة. مجدداً، من غير المعروف ما إذا كانت هذه الأعراض بسبب استخدام سيروكسات سي.آر. أم لا. الأعراض هي:</p><ul><li dir="RTL">صعوبة&nbsp; في التنفس</li><li dir="RTL">زرقة الجلد أو برودة أو سخونة شديدة</li><li dir="RTL">التقيؤ أو عدم الرضاعة بشكل صحيح</li><li dir="RTL">التعب الشديد، عدم القدرة على النوم أو بكاء مستمر</li><li dir="RTL">تصلب أو ليونة العضلات</li><li dir="RTL">رعاش، هياج أو نوبات</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; إذا كان طفلك لديه أي من هذه الأعراض عند الولادة، أوكنت قلقة حول صحة طفلك، <strong>إتصلي بطبيبك أوالقابلة للنصيحة</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مكونات سيروكسات سي.آر. تستطيع أن تَمُر إلى حليب الثدي. <strong>إذا كنتِ تقومين بالرضاعة الطبيعية، يجب أن تراجعي طبيبك</strong> قبل استعمال سيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقاقير مثل سيروكسات سي.آر. قد تؤثر على الحيوانات المنوية لديك. الخصوبة قد تقل في بعض الرجال أثناء العلاج بسيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">سيروكسات سي.آر. قد يجعلك تشعر بدوار أو ارتباك ويؤثر على رؤيتك.</p><p dir="RTL">&not;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تقوم بالقيادة أو استخدام الآلات</strong> إذا حدث لك مثل هذه الأعراض الجانبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>دائما استعمل سيروكسات سي.آر. كما أخبرك الطبيب</strong>. تأكد من طبيبك او الصيدلي إذا كنت لست متأكدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهي جرعة سيروكسات سي.آر.&nbsp; التي يجب تناولها</strong></p><p dir="RTL"><strong>الجرعة الأولية</strong> من سيروكسات سي.آر. تعتمد على مرضك. هي عادة 12.5ملجم أو 25ملجم مرة واحدة يوميا. قد يزيد طبيبك الجرعة الخاصة بك تدريجيا للتحكم في الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان سنك أكبر من 65 عاماً أو لديك مشاكل في الكبد أو الكلى، الجرعة القصوى قد يتم تخفيضها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية الاستعمال</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ابتلع قرص سيروكسات سي.آر. كاملاً مع بعض الماء. لا تمضغ أو تحطم أو تقسم القرص</strong>- إذا فعلت، هناك خطر زيادة الجرعة، لأن الدواء قد يطلق في جسمك بسرعة كبيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استعمل سيروكسات سي.آر. في الصباح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تستطيع أن تستعمل سيروكسات سي.آر. مع أو بدون طعام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب على مقدمات الرعاية الحوامل تجنب التعرض لأقراص سيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ماهي المدة اللازمة للاستعمال</strong></p><p dir="RTL">مدة العلاج تعتمد على حالتك المرضية. بينما اللأشخاص يشعرون ببعض التحسن خلال أسبوعين، قد يستغرق الدواء وقتاً أطول ليصل إلى الفعالية الكاملة.</p><p dir="RTL">حتى لو بدأت تشعر بأنك أفضل، من المهم أن تستخدم سيروكسات سي.آر. كما أوصاك طبيبك لمنع الأعراض من العودة. هذا قد يستغرق عدة أشهر بعد التعافي من الاكتئاب وقد يستغرق وقتاً أطول لحالات الهلع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تناول سيروكسات سي.آر.</strong></p><p dir="RTL"><strong>لا تتناول جرعة إضافية</strong> لتعوض الجرعة المنسية. فقط تناول جرعتك القادمة في وقتها المعتاد.</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>إذا لم تكن متأكدا مما ستفعل،</strong> اسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت سيروكسات سي.آر. أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت سيروكسات سي.آر. أكثر من اللازم ستكون معرض أكثر للإصابة بالأعراض الجانبية (انظر <strong>ال</strong><strong>فقرة 4</strong>). تناول سيروكسات سي.آر. أكثر من اللازم قد يسبب أيضا تغيرات في ضغط الدم، إنقباضات عضلية لاإرادية، قلق، إرتفاع في درجة الحرارة، وضربات قلب سريعة.</p><p dir="RTL">&not;&nbsp;&nbsp; إذا تناولت سيروكسات سي.آر. أكثر من اللازم، <strong>اتصل بطبيبك أو الصيدلي للنصيحة</strong>. إذا كان بالإمكان، أظهر لهم عبوة سيروكسات سي.آر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا توقف استعمال سيروكسات سي.آر. بدون نصيحة</strong></p><p dir="RTL"><strong>لا توقف استعمال سيروكسات سي.آر. قبل أن تتحدث إلى طبيبك أولاً</strong>. جرعتك تحتاج لأن تقل تدريجيا، عدا ذلك قد تصاب بأعراض جانبية (انظر &rsquo;أعراض تشاهد عند إيقاف سيروكسات سي.آ<em>ر.&lsquo;</em> في نهاية <strong>الفقرة 4</strong>)</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، سيروكسات سي.آر. قد يسبب أعراضاً جانبية، لكنها لا تصيب كل شخص.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات يجب الحذر منها</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تفاعلات الحساسية الشديدة. وتكون نادرة جداً في الأشخاص الذين يستعملون سيروكسات سي.آر. العلامات تشمل:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي بارز ومصحوب بحكة (شرى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ، أحيانا في الوجه أو الفم (وذمة وعائية)، تسبب صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انهيار أو فقدان للوعي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&not;&nbsp;&nbsp; </strong><strong>اتصل بطبيبك على الفور إذا أصبت بهذه الأعراض. توقف عن تناول سيروكسات سي.آر.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متلازمة سيروتينين والمتلازمة الخبيثة للعقار المضاد للذهان</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">العقاقير التي قد تزيد من نشاط السيروتينين في المخ قد تسبب حالة تسمى متلازمة سيروتينين. هذا عرض جانبي نادر جداً مع سيروكسات سي.آر. استعمال سيروكسات سي.آر. مع عقاقير أخرى قد يرفع من نشاط السيروتينين في المخ، قد يزيد من احتمالية حدوث أعراض جانبية خطيرة (انظر <em>&rsquo;سيروكسات وأدوية أخرى&lsquo;</em> في <strong>الفقرة 2</strong>). حالة أخرى تسمى المتلازمة الخبيثة للعقار المضاد للذهان هي عرض جانبي نادر الحدوث مع العقاقير التي تستخدم في علاج مشاكل العقل الصحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض نفسها لكل من متلازمة السيروتينين و المتلازمة الخبيثة للعقار المضاد للذهان. عادة أكثر من واحد من الأعراض التالية سيحدث:</p><ul><li dir="RTL">رجفة</li><li dir="RTL">حركات لا إرادية مفاجئة متشنجة</li><li dir="RTL">تصلب في العضلات</li><li dir="RTL">صعوبة في الجلوس</li><li dir="RTL">شعور بانفعال شديد أو اضطراب</li><li dir="RTL">الإحساس بالحر أو التعرق</li><li dir="RTL">زيادة في معدل ضربات القلب</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">شدة العرض يمكن أن تزداد، مما يؤدي إلى فقدان الوعي.</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>اتصل بطبيبك على الفور</strong>، إذا كان لديك أي من هذه الأعراض</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التململ</strong></p><p dir="RTL">العقاقير التي تستخدم لعلاج مشاكل الصحة العقلية قد تسبب إحساس داخلي بعدم الراحة ورغبة ملحة في الحركة (تململ). هذا العرض نادر الحدوث مع سيروكسات سي.آر.، غالباً ما يحدث في الأسابيع الأولى القليلة من العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>أخبر طبيبك في أقرب وقت ممكن</strong> إذا أصبت بأي من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة جداً</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تصيب <strong>أكثر من فرد واحد من كل 10 </strong>أفراد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالتعب (غثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في الرغبة الجنسية أو الوظيفة الجنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تصيب <strong>حتى فرد واحد من كل 10</strong> أفراد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في النوم (أرق) أو شعور بالنعاس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالهياج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح في الروية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثاؤب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف في الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالمرض (قيء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحلام غير معتادة (تشمل الكوابيس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية شائعة قد تظهر في اختبارات الدم</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الكوليسترول</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تصيب <strong>حتى فرد واحد من كل 100</strong> فرد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدم أو نزف غير معتاد بشكل رئيسي في الجلد والمناطق الرطبة مثل الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالارتباك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو سماع أشياء غير موجودة في الواقع (<em>هلوسة</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات عضلية لا إرادية في الوجه، حركات التوائية في الجسد، الذراعين والقدمين، ارتعاش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; توسع الحدقة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب أسرع من المعتاد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم&nbsp; (قد يسبب دوار، خفة في الرأس أو غشيان عند الوقوف من وضعية الجلوس أو الاستلقاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التبول (<em>احتباس بولي</em>) أو فقدان التحكم في المثانة (<em>السلس البولي</em>)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تصيب <strong>حتى فرد واحد من كل 1000</strong> فرد:</p><ul><li dir="RTL">شعور بعدم الراحة وصعوبة في الجلوس أو استمرار الوقوف (تململ)</li><li dir="RTL">نوبات من النشاط الزائد، انشاء واضطراب (هوس)</li><li dir="RTL">نوبات (تشنجات)</li><li dir="RTL">رغبة ملحة لا يمكن مقاومتها لتحريك القدمين (متلازمة عدم راحة القدمين)</li><li dir="RTL">إفراز غير طبيعي لحليب الثدي لدى الرجال والنساء</li><li dir="RTL">اضطرابات الدورة الشهرية (تشمل الدورات الثقيلة، النزف بين الدورات وغياب الدورات).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة قد تظهر في اختبارات الدم</strong><strong>:</strong></p><ul><li dir="RTL">نقص مستوى الصوديوم في الدم (خاصة في كبار السن)</li><li dir="RTL">زيادة في المواد (<em>الإنزيمات</em>) من الكبد</li><li dir="RTL">زيادة في هرمون يدعى برولاكتين</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة جداً</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">قد تصيب <strong>حتى فرد واحد من كل 10.000</strong> فرد:</p><ul><li dir="RTL">متلازمة السيروتينين</li><li dir="RTL">طفح جلد، قد يكون مع بثور، ويظهر مثل علامة صغير (بقع صغيرة في الوسط محاطة بمنطقة أفتح مع دائرة داكنة على الحافة) تدعى حمامي عديدة الأشكال</li><li dir="RTL">طفح منتشر مع بثور وجلد متقشر، خصوصاً حول الفم، الأنف، العينين والأعضاء التناسلية (متلازمة ستيفنز جونز)</li><li dir="RTL">طفح منتشر مع بثور وجلد متقشر على أغلب سطح الجسم (تنخر الأنسجة الجلدية السام)</li><li dir="RTL">زيادة كميات الهرمون المضاد لإدرار البول &nbsp;الذي يسبب احتباس الماء</li><li dir="RTL">الماء الأزرق (حالة بسبب زيادة ضغط العين)</li><li dir="RTL">نزيف في الجهاز الهضمي (وجود دم في البراز أو براز أسود اللون)</li><li dir="RTL">التهاب الكبد، أحيانا يسبب اصفرار في الجلد أو في بياض العينين (يرقان)</li><li dir="RTL">زيادة حساسية الجلد للضوء</li><li dir="RTL">تورم اليدين، الكاحلين أو القدمين.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية نادرة جدا قد تظهر في اختبارات الدم</strong><strong>:</strong></p><ul><li dir="RTL">نقص في عدد الصفائح الدموية (خلايا تساعد على تخثر الدم).</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أصبت بأعراض جانبية</strong></p><p dir="RTL">&not;&nbsp;&nbsp; <strong>أخبر طبيبك أو الصيدلي</strong> إذا كان أي من الأعراض المذكورة أصبحت <strong>شديدة أو مزعجة</strong>. أو إذا لاحظت أعراض جانبية غير مذكورة في النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض تشاهد عند إيقاف سيروكسات سي.آر</strong><strong>.</strong></p><p dir="RTL">إيقاف العقاقير التي تستخدم في علاج المشاكل الصحية العقلية غالبا يسبب أعراض جانبية غير مرغوب بها. الأعراض غالباً ما تحدث في الأيام الأولى لتوقف تناول العقار وتختفي بعد أسابيع قليلة.</p><p dir="RTL">إذا كنت تحتاج لإيقاف تناول سيروكسات سي.آر.، قد يخفض طبيبك الجرعة تدريجيا. وهذا يساعد على التقليل من أي آثار وخطورتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض شائعة تلاحظ عند إيقاف سيروكسات سي.آر</strong><strong>. </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تصيب <strong>حتى فرد واحد من كل 10</strong> أفراد:</p><ul><li dir="RTL">دوار</li><li dir="RTL">شعور بوخز الإبر، إحساس بصدمات كهربائية وإزعاج مستمر في الأذن (طنين)</li><li dir="RTL">اضطرابات في النوم تشمل الأحلام العميقة</li><li dir="RTL">شعور بالقلق</li><li dir="RTL">صداع</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية غير شائعة تلاحظ عند إيقاف سيروكسات سي.آر</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تصيب <strong>حتى فرد واحد من كل 100</strong> فرد:</p><ul><li dir="RTL">الشعور بعدم الراحة أو التهيج</li><li dir="RTL">الشعور بالمرض (غثيان)</li><li dir="RTL">رجفان</li><li dir="RTL">الشعور بالإرتباك</li><li dir="RTL">تعرق</li><li dir="RTL">إسهال</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&not;&nbsp;&nbsp; <strong>تحدث إلى طبيبك</strong> إذا أصبحت هذه الأعراض <strong>حادة أو مزعجة</strong>.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ بعيداً عن متناول ونظر الأطفال.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز استعمال سيروكسات سي.آر. بعد تاريخ انتهاء الصلاحية المبين على العبوة بعد كلمة &quot;Exp&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ سيروكسات سي.آر. في درجة حرارة أقل من 25&deg;م. قم بحفظه في عبوته الأصلية في مكان جاف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بوقف تناول سيروكسات سي.آر.، فمن المهم إعادة أي كمية متبقية إلى الصيدلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز التخلص من الأدوية في مياه الصرف الصحي أو المخلفات المنـزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد على وقاية البيئة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب نقل و تخزين سيروكسات سي.آر عبوته الأصلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي سيروكسات سي.آر.</strong></p><p dir="RTL">المادة الفعالة هي پاروكسيتين كپاروكستين هيدروكلورايد هيمي-هيدرات</p><p dir="RTL">أقراص سيروكسات سي.آر. تأتي بتركيزات مختلفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كل قرص يحتوي على إما:</p><p dir="RTL">12.5ملجم أو 25ملجم من پاروكسيتين هيدروكلورايد هيمي-هيدرات</p><p dir="RTL">&nbsp;</p><p dir="RTL">مواد أخرى غير فعالة:</p><p dir="RTL">هيبروميلوز، بوڤيدون، لاكتوز مونوهيدريت، ستيريت الماغنيسيوم، ثاني أوكسيد السيليكون الغروي، جليسريل بيهينيت، محلول مشتت كوبولايمر حمض ميثاكريليك، تالك، سيتريت ثلاثي الإيثيل، أوبادري أصفر YS-1- 2007 (أقراص 12.5ملجم)، أوبادري وردي اللون Y-1-1262 (أقراص 25ملجم) والملونات التالية: أكسيد الحديد الأصفر (أقراص 12.5ملجم)&nbsp; وأكسيد الحديد الأحمر (أقراص 25ملجم)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو شكل سيروكسات سي.آر. وماهي محتويات العبوة</strong></p><p dir="RTL">أقراص 12.5ملجم: صفراء، محفور عليها شعار GSK &nbsp;على أحد الأوجه و 12.5 على الوجه الآخر.</p><p dir="RTL">أقراص 25ملجم: وردية، محفور عليها شعار GSK &nbsp;على أحد الأوجه و 25 على الوجه الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أقراص سيروكسات سي.آر.12.5ملجم: عبوات فقاعية بشريط ألمنيوم أو قوارير بلاستيكية مع أغطية مقاومة عبث الأطفال.</p><p dir="RTL">أقراص سيروكسات سي.آر.25ملجم: عبوات فقاعية بشريط ألمنيوم أو قوارير بلاستيكية مع أغطية مقاومة عبث الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تسوق كل العبوات في كل بلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>سيروكسات</em></strong> علامة تجارية مملوكة أو مرخصة&nbsp; لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2024 مجموعة شركات جلاكسو سميث كلاين. جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">بورا فارماسيوتيكال سيرفس إنك، ميسيساكا، كندا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الشركة المالكة لرخصة التسويق:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL">*عضو مجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية</strong><strong>:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><ul><li dir="RTL">هاتف: 6536666-12-966+</li><li dir="RTL">جوال: 9882-904-56-966+</li><li dir="RTL">البريد الإلكتروني: &nbsp;gcc.medinfo@gsk.com</li><li dir="RTL">الموقع الإلكتروني: &nbsp;https://gskpro.com/en-sa/&nbsp;&nbsp;</li><li dir="RTL">ص.ب. 55850، جدة 21544، المملكة العربية السعودية.</li></ul><p dir="RTL"><!--[if gte vml 1]><v:roundrect
 id="AutoShape_x0020_8" o:spid="_x0000_s1026" style='position:absolute;left:0;
 text-align:left;margin-left:13.95pt;margin-top:16.5pt;width:496.9pt;height:231.5pt;
 z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' arcsize="10923f"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" strokeweight="2.5pt">
 <v:shadow color="#868686"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><b><span lang=AR-SA
    style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif'>للإبلاغ
    عن أية آثار جانبية:</span></b><b><span lang=EN-US dir=LTR style='font-size:
    14.0pt;line-height:107%;font-family:"Times New Roman",serif'><o:p></o:p></span></b></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><b><i><span
    lang=AR-SA style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif'>المملكة
    العربية السعودية</span></i></b><b><i><span lang=EN-US dir=LTR
    style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif'><o:p></o:p></span></i></b></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><span dir=RTL></span><span
    dir=RTL></span><b><span lang=AR-SA style='font-size:14.0pt;line-height:
    107%;font-family:"Times New Roman",serif'><span dir=RTL></span><span
    dir=RTL></span>- المركز الوطني للتيقظ والسلامة الدوائية</span></b><b><span
    lang=EN-US dir=LTR style='font-size:14.0pt;line-height:107%;font-family:
    "Times New Roman",serif'><o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;text-indent:
    -.25in;line-height:normal;mso-list:l0 level1 lfo1'><![if !supportLists]><span
    lang=EN-US style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:
    Symbol;mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif'>الاتصال
    بالرقم الموحد: 19999<o:p></o:p></span></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;text-indent:
    -.25in;line-height:normal;mso-list:l0 level1 lfo1'><![if !supportLists]><span
    class=MsoHyperlink><span lang=EN-US style='font-size:10.0pt;font-family:
    Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
    color:windowtext;text-decoration:none;text-underline:none'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=RTL></span><span
    lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif'>البريد
    الإلكتروني: </span><span lang=EN-US><a href="mailto:npc.drug@sfda.gov.sa"><span
    dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif'>npc.drug@sfda.gov.sa</span></a></span><span
    class=MsoHyperlink><span lang=EN-US dir=LTR style='font-size:12.0pt;
    font-family:"Times New Roman",serif'><o:p></o:p></span></span></p>
    <p class=MsoListParagraph dir=RTL style='text-indent:-.25in;line-height:
    normal;mso-list:l0 level1 lfo1'><![if !supportLists]><span
    class=MsoHyperlink><span lang=EN-US style='font-size:10.0pt;font-family:
    Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol;
    color:windowtext;text-decoration:none;text-underline:none'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span></span><![endif]><span dir=RTL></span><span
    lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif'>الموقع
    الإلكتروني:<span class=MsoHyperlink> </span></span><span lang=EN-US><a
    href="https://ade.sfda.gov.sa/"><span dir=LTR style='font-size:12.0pt;
    font-family:"Times New Roman",serif'>https://ade.sfda.gov.sa</span></a></span><span
    class=MsoHyperlink><span lang=EN-US dir=LTR style='font-size:12.0pt'><o:p></o:p></span></span></p>
    <p class=MsoNormal dir=RTL style='margin-bottom:0in'><span dir=RTL></span><span
    dir=RTL></span><b><span lang=AR-SA style='font-size:14.0pt;line-height:
    107%;font-family:"Times New Roman",serif'><span dir=RTL></span><span
    dir=RTL></span>- جلاكسو سميث كلاين – المكتب الرئيسي، جدة.</span></b><b><span
    dir=LTR style='font-size:14.0pt;line-height:107%;font-family:"Times New Roman",serif;
    mso-ansi-language:EN-GB'><o:p></o:p></span></b></p>
    <p class=MsoListParagraph dir=RTL style='margin-bottom:0in;mso-add-space:
    auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;
    tab-stops:right 13.5pt'><![if !supportLists]><span lang=EN-US
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif'>هاتف:
    6536666 </span><span dir=LTR></span><span dir=LTR></span><span lang=EN-US
    dir=LTR style='font-size:12.0pt;font-family:"Times New Roman",serif'><span
    dir=LTR></span><span dir=LTR></span>-</span><span dir=RTL></span><span
    dir=RTL></span><span lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif'><span
    dir=RTL></span><span dir=RTL></span>12</span><span dir=LTR></span><span
    dir=LTR></span><span lang=EN-US dir=LTR style='font-size:12.0pt;font-family:
    "Times New Roman",serif'><span dir=LTR></span><span dir=LTR></span>-</span><span
    dir=RTL></span><span dir=RTL></span><span lang=AR-SA style='font-size:12.0pt;
    font-family:"Times New Roman",serif'><span dir=RTL></span><span dir=RTL></span>
    966 +<o:p></o:p></span></p>
    <ul style='margin-top:0in' type=disc>
     <li class=MsoNormal dir=RTL style='margin-bottom:0in;line-height:115%;
         mso-list:l1 level1 lfo2;tab-stops:list .5in'><span lang=AR-SA
         style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif'>جوال:
         9882-904-56-966+<o:p></o:p></span></li>
    </ul>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='text-indent:-.25in;
    mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-US style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif'>البريد
    الإلكتروني: </span><span class=MsoHyperlink><span lang=EN-US dir=LTR
    style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif'>s</span></span><span
    lang=EN-US dir=LTR><a href="mailto:Saudi.safety@gsk.com"><span
    style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif'>audi.safety@gsk.com</span></a></span><span
    lang=EN-US dir=LTR style='font-size:12.0pt;line-height:115%;font-family:
    "Times New Roman",serif'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='text-indent:-.25in;
    mso-list:l0 level1 lfo1;tab-stops:right 13.5pt'><![if !supportLists]><span
    lang=EN-US style='font-size:10.0pt;line-height:115%;font-family:Symbol;
    mso-fareast-font-family:Symbol;mso-bidi-font-family:Symbol'><span
    style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif'>الموقع
    الإلكتروني: </span><span class=MsoHyperlink><span lang=EN-US dir=LTR
    style='font-size:12.0pt;line-height:115%;font-family:"Times New Roman",serif'>https://gskpro.com/en-sa/</span></span><span
    lang=EN-US dir=LTR style='font-size:12.0pt;line-height:115%;font-family:
    "Times New Roman",serif'> <o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-bottom:0in;
    mso-add-space:auto;text-indent:-.25in;line-height:normal;mso-list:l0 level1 lfo1;
    tab-stops:right 13.5pt'><![if !supportLists]><span lang=EN-US
    style='font-size:10.0pt;font-family:Symbol;mso-fareast-font-family:Symbol;
    mso-bidi-font-family:Symbol'><span style='mso-list:Ignore'>·<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></span><![endif]><span
    dir=RTL></span><span lang=AR-SA style='font-size:12.0pt;font-family:"Times New Roman",serif'>ص.ب
    55850، جدة 21544، المملكة العربية السعودية</span><span lang=AR-SA
    style='font-size:12.0pt;font-family:"Traditional Arabic",serif'>.</span><span
    lang=EN-US dir=LTR style='font-size:12.0pt;font-family:"Traditional Arabic",serif'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="669" height="315" alt="Rectangle: Rounded Corners: للإبلاغ عن أية آثار جانبية:
المملكة العربية السعودية
- المركز الوطني للتيقظ والسلامة الدوائية
•	الاتصال بالرقم الموحد: 19999
•	البريد الإلكتروني: npc.drug@sfda.gov.sa
•	الموقع الإلكتروني: https://ade.sfda.gov.sa
- جلاكسو سميث كلاين – المكتب الرئيسي، جدة.
•	هاتف: 6536666 -12- 966 +
•	جوال: 9882-904-56-966+
•	البريد الإلكتروني: saudi.safety@gsk.com
•	الموقع الإلكتروني: https://gskpro.com/en-sa/ 
•	ص.ب 55850، جدة 21544، المملكة العربية السعودية.
" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مستخرج من GDS رقم: 49
تاريخ الإصدار:16 جولاي 2024

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Paroxetine hydrochloride hemihydrate
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each SEROXAT CR (controlled release) tablet contains paroxetine hydrochloride hemihydrate equivalent to 12.5 mg or 25 mg paroxetine free base.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Controlled release tablets
SEROXAT 12.5 mg tablets: Yellow, round, biconvex tablets with GSK engraved on one side and 12.5 on the other side.
SEROXAT 25 mg tablets: Pink, round, biconvex tablets with GSK engraved on one side and 25 on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_95810fe3-0514-4094-88f0-12305fa8b746
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>Major Depressive Disorder:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_dc33be1e-6980-4686-a34f-ed26bf7e5ad6
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>SEROXAT</em> CR tablets are indicated for the treatment of major depressive disorder (MDD).</p><p><strong>Panic Disorder:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_8bdbc0c8-67e6-49f5-a333-068a0c527522
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>SEROXAT</em> CR tablets have been shown to be effective in the treatment of panic disorder with or without agoraphobia.</p><p><strong>Premenstrual Dysphoric Disorder:</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_eb0b0c3a-40b7-4a43-b619-81d44316bfa5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>SEROXAT</em> CR tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD).</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Social Anxiety Disorder/Social Phobia:</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1523f3b9-488b-4004-9321-a13d6d659094 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>SEROXAT</em> CR Tablets have been shown to be effective in the treatment of Social Anxiety Disorder/Social Phobia.</p><p>The effectiveness of <em>SEROXAT</em> CR tablets in the long-term treatment of Social Anxiety Disorder/Social Phobia has not been evaluated. Therefore, if <em>SEROXAT</em> CR tablets are to be administered for extended periods in the treatment of Social Anxiety Disorder/Social Phobia, the physician should periodically re-evaluate the long-term usefulness of <em>SEROXAT </em>CR for the individual patient.</p><p><strong>Children and adolescents (less than 18&nbsp;years)</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_941d0dcb-a47a-4c18-a4f6-07e9cdfe8c2b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>All Indications:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_0e5d32c6-7a3d-4eca-9df2-ef8343bf1781
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>SEROXAT</em> CR is not indicated for use in children or adolescents aged less than 18&nbsp;years (<em>see Warnings and Precautions</em>).</p><p>The efficacy of <em>SEROXAT</em> CR tablets has not been studied in children or adolescents aged less than 18&nbsp;years; however, controlled clinical studies with <em>SEROXAT</em> IR (immediate release) tablets in children and adolescents with major depressive disorder failed to demonstrate efficacy, and do not support the use of <em>SEROXAT</em> in the treatment of depression in this population (<em>see Warnings and Precautions</em>).</p><p>The safety and efficacy of <em>SEROXAT</em> in children aged less than 7&nbsp;years has not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_9f193d15-120a-4651-914e-c38231069d0a
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>SEROXAT</em> CR tablets should be administered as a single daily dose, usually in the morning, with or without food. Patients should be informed that <em>SEROXAT</em> CR tablets should not be chewed or crushed, and should be swallowed whole.</p><p><strong>Major Depressive Disorder:</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f6438ebd-8b84-4b66-bc1e-09e7a42c3c44 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The recommended initial dose is 25 mg/day.&nbsp; Some patients not responding to a 25 mg dose may benefit from dose increases in 12.5 mg/day increments, up to a maximum of 62.5 mg/day according to patient response.&nbsp; Dose changes should occur at intervals of at least 1 week.</p><p>As with all antidepressant drugs, dosage should be reviewed and adjusted, if necessary, within 2 to 3 weeks of initiation of therapy and thereafter as judged clinically appropriate.</p><p>Patients with depression should be treated for a sufficient period to ensure that they are free from symptoms. This period may be several months.</p><p>&nbsp;</p><p><strong>Panic Disorder:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_797ca3b0-0e22-48a5-b1b0-c4b2efd873ee
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Patients should begin treatment on 12.5 mg/day and the dose increased weekly in 12.5&nbsp;mg/day increments according to patient response.&nbsp; Some patients may benefit from having their dose increased up to a maximum of 75 mg/day.</p><p>A low initial starting dose is recommended to minimise the potential worsening of panic symptomatology which is generally recognised to occur early in the treatment of this disorder.</p><p>Patients with panic disorder should be treated for a sufficient period to ensure that they are free from symptoms. This period may be several months or even longer.</p><p><strong>Premenstrual Dysphoric Disorder:</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ea976271-80fe-4ca1-a724-d5fb98842116 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The recommended initial dose is 12.5 mg/day.&nbsp; Some patients not responding to a 12.5&nbsp;mg dose may benefit from having their dose increased to 25 mg/day. Dose changes should occur at intervals of at least 1 week.</p><p>Patients with PMDD should be periodically assessed to determine the need for continual treatment.</p><p><strong>Social Anxiety Disorder/Social Phobia:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_42b94d1d-b46b-4ff6-9648-a7baa75e5e6e
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The recommended initial dose is 12.5 mg daily.&nbsp; Some patients not responding to a 12.5&nbsp;mg dose may benefit from having dose increases in 12.5 mg/day increments as required, up to a maximum of 37.5 mg/day according to the patient&#39;s response. Dose changes should occur at intervals of at least 1 week.</p><p><strong>General Information</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_354eed70-415e-4143-b283-579fdbfbaa03
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><strong>Other Populations</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_46141dbc-2a67-4bf0-8bce-fa44b58664d1
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>Elderly:</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_15b06562-b419-4ae3-9446-9a0294c13b1c
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></i><![endif]--></p><p>Increased plasma concentrations of paroxetine occur in elderly subjects, but the range of concentrations overlaps with that observed in younger subjects.</p><p>Dosing should commence at 12.5 mg/day and may be increased up to 50 mg/day.</p><p><em>Children and adolescents (less than 18 years):</em><!--[if supportFields]><i style='mso-bidi-font-style:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b7d5f295-e24a-4924-beb2-249dffb729d7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></i><![endif]--></p><p><em>SEROXAT</em> CR is not indicated for use in children or adolescents aged less than 18&nbsp;years (<em>see Indications, Warnings and Precautions</em>).</p><p><em>Renal/hepatic impairment:</em><!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_4c0c69b8-5ca0-4c8b-bf28-3c0e41f913f1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Increased plasma concentrations of paroxetine occur in patients with severe renal impairment (creatinine clearance &lt;30&nbsp;mL/min) or in those with<strong><em> </em></strong>hepatic impairment. The dosage should be restricted to the lower end of the range.</p><p><strong>DISCONTINUATION OF <em>SEROXAT</em></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
VAULT_ND_5b279596-388e-43a7-a08b-2febb6dffe68 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>As with other psychoactive medications, abrupt discontinuation should generally be avoided (<em>see Warnings and Precautions and Adverse Reactions</em>). The taper phase regimen used in recent clinical trials involved a decrease in the daily dose by 10&nbsp;mg/day (equivalent to 12.5 mg/day CR tablets) at weekly intervals.</p><p>When a daily dose of 20&nbsp;mg/day (equivalent to 25 mg/day CR tablets) was reached, patients were continued on this dose for 1 week before treatment was stopped. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Known hypersensitivity to paroxetine and excipients.
SEROXAT CR tablets should not be used in combination with monoamine oxidase (MAO) inhibitors (including linezolid, an antibiotic which is a reversible non selective MAO inhibitor and methylthioninium chloride (methylene blue)) or within two weeks of terminating treatment with MAO inhibitors. Likewise, MAO inhibitors should not be introduced within two weeks of cessation of therapy with SEROXAT CR tablets (see Interactions).
SEROXAT CR should not be used in patients receiving medications that can prolong QT interval and are also metabolised by CYP450 2D6, such as thioridazine or pimozide (see Interactions).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Children and Adolescents (less than 18&nbsp;years)</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_df4cf990-ee19-4f40-9165-1751550ea609
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Treatment with antidepressants is associated with an increased risk of suicidal thinking and behaviour in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders.<strong><em> </em></strong>In clinical trials of <em>SEROXAT</em> in children and adolescents, adverse events related to suicidality (suicide attempts and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in patients treated with <em>SEROXAT</em> compared to those treated with placebo (<em>see Adverse Reactions</em>). Long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p><strong>Clinical worsening and suicide risk in adults</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1fafdab3-8956-4204-9108-37f57179916f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Young adults, especially those with MDD, may be at increased risk for suicidal behaviour during treatment with <em>SEROXAT</em> CR. An analysis of placebo-controlled trials of adults with psychiatric disorders showed a higher frequency of suicidal behaviour in young adults (prospectively defined as aged 18 to 24&nbsp;years) treated with paroxetine compared with placebo (17/776 [2.19%] versus 5/542 [0.92%]), although this difference was not statistically significant.&nbsp; In the older age groups (aged 25 to 64&nbsp;years and &ge;65 years), no such increase was observed.&nbsp; In adults with MDD (all ages), there was a statistically significant increase in the frequency of suicidal behaviour in patients treated with paroxetine compared with placebo (11/3455 [0.32%] versus 1/1978 [0.05%]; all of the events were suicide attempts).&nbsp; However, the majority of these attempts for paroxetine (8&nbsp;of 11) were in younger adults aged 18 to 30&nbsp;years.&nbsp; These MDD data suggest that the higher frequency observed in the younger adult population across psychiatric disorders may extend beyond the age of 24.&nbsp;</p><p>Patients with depression may experience worsening of their depressive symptoms and/or the emergence of suicidal ideation and behaviours (suicidality) whether or not they are taking antidepressant medications. This risk persists until significant remission occurs. It is general clinical experience with all antidepressant therapies that the risk of suicide may increase in the early stages of recovery. Other psychiatric conditions for which <em>SEROXAT</em> is prescribed can be associated with an increased risk of suicidal behaviour, and these conditions may also be co-morbid with MDD. Additionally, patients with a history of suicidal behaviour or thoughts, young adults, and those patients exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are at a greater risk of suicidal thoughts or suicide attempts. All patients should be monitored for clinical worsening (including development of new symptoms)<strong><em> </em></strong>and suicidality throughout treatment, and especially at the beginning of a course of treatment, or at the time of dose changes, either increases or decreases.</p><p>Patients (and caregivers of patients) should be alerted about the need to monitor for any worsening of their condition (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour or thoughts of harming themselves and to seek medical advice immediately if these symptoms present.&nbsp; It should be recognised that the onset of some symptoms, such as agitation, akathisia or mania, could be related either to the underlying disease state or the drug therapy (<em>see Akathisia and Mania and Bipolar Disorder below; Adverse Reactions</em>).</p><p>Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients who experience clinical worsening (including development of new symptoms) and/or the emergence of suicidal ideation/behaviour, especially if these symptoms are severe, abrupt in onset, or were not part of the patient&rsquo;s presenting symptoms.</p><p><strong>Akathisia</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_c88cf683-dc6c-4470-9fdb-80cb6a846cb1
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Rarely, the use of <em>SEROXAT </em>or other selective serotonin reuptake inhibitors (SSRIs) have been associated with the development of akathisia, which is characterised by an inner sense of restlessness and psychomotor agitation such as an inability to sit or stand still usually associated with subjective distress. This is most likely to occur within the first few weeks of treatment.</p><p><strong>Serotonin Syndrome/Neuroleptic Malignant Syndrome</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_fa37778f-fff5-4595-a59c-21ee206cac15
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>On rare occasions development of a serotonin syndrome or neuroleptic malignant syndrome-like events may occur in association with <em>SEROXAT</em> treatment, particularly when given in combination with other serotonergic and/or neuroleptic drugs.&nbsp; As these syndromes may result in potentially life-threatening conditions, treatment with <em>SEROXAT</em> should be discontinued if such events (characterised by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated. <em>SEROXAT</em> should not be used in combination with serotonin-precursors (such as L-tryptophan, oxitriptan) due to the risk of serotonergic syndrome<em> (see Contraindications, Interactions).</em></p><p><strong>Mania and Bipolar disorder</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_97d04df8-8956-4a99-bd70-82803b70150b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone can increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder.&nbsp; Prior to initiating treatment with an antidepressant, patients should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that paroxetine is not approved for use in treating bipolar depression.&nbsp; As with all antidepressants, paroxetine should be used with caution in patients with a history of mania.</p><p>Tamoxifen<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman Bold",serif;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:"Times New Roman";mso-ansi-language:
EN-GB;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_f6452013-07a9-4823-9002-e6746891b533 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman Bold",serif;mso-fareast-font-family:
"Times New Roman";mso-bidi-font-family:"Times New Roman";mso-ansi-language:
EN-GB;layout-grid-mode:line'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced when co-prescribed with <em>SEROXAT </em>CR as a result of paroxetine&rsquo;s irreversible inhibition of CYP2D6 (<em>see Interactions</em>).&nbsp; This risk may increase with longer duration of co-administration. When tamoxifen is used for the treatment or prevention of breast cancer, prescribers should consider using an alternative antidepressant with little or no CYP2D6 inhibition.</p><p><strong>Bone fracture</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;font-family:"Times New Roman Bold",serif;
mso-fareast-font-family:"Times New Roman";mso-bidi-font-family:"Times New Roman";
mso-ansi-language:EN-GB;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e75c0d57-6a00-48a3-96c0-b4a2755bf636 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman Bold",serif;mso-fareast-font-family:"Times New Roman";
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-GB;layout-grid-mode:
line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Epidemiological studies on bone fracture risk following exposure to some antidepressants, including SSRIs, have reported an association with fractures. The risk occurs during treatment and is greatest in the early stages of therapy. The possibility of fracture should be considered in the care of patients treated with <em>SEROXAT</em><strong> </strong>CR.</p><p><strong>Monoamine Oxidase Inhibitors</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a309d8b8-b62e-40ff-bef7-3a22463e8b49 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Treatment with <em>SEROXAT</em><strong> </strong>CR should be initiated cautiously at least two weeks after terminating treatment with MAO inhibitors and dosage of <em>SEROXAT</em><strong> </strong>CR should be increased gradually until optimal response is reached (<em>see Contraindications, Interactions</em>).</p><p><strong>Renal/hepatic impairment</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_b9a37b79-d9a4-46d5-bacb-8692ace0ec98
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Caution is recommended in patients with severe renal impairment or in those with hepatic impairment<strong><em> </em></strong><em>(see Dosage and Administration).</em></p><p><strong>Epilepsy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_ef3df155-9322-4c83-a8e8-8e2762a47100
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>As with other antidepressants, <em>SEROXAT</em><strong> </strong>CR should be used with caution in patients with epilepsy.</p><p><strong>Seizures</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_a9c61d0d-4c85-4782-9044-97088856a8bd
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Overall the incidence of seizures is less than 0.1% in patients treated with paroxetine.&nbsp; The drug should be discontinued in any patient who develops seizures.</p><p><strong>Electroconvulsive therapy (ECT)</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_909cc656-c2ed-4463-8c27-e7cb9a4495e3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>There is little clinical experience of the concurrent administration of paroxetine with ECT.</p><p><strong>Glaucoma</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_b3128eca-711c-4e7f-aa1c-9641e9047e69
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>As with other SSRIs, paroxetine can cause mydriasis and should be used with caution in patients with narrow angle glaucoma.</p><p><strong>Hyponatraemia</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_4ed651a7-8c58-4498-98bf-3a3b8a61eef7
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>Hyponatraemia has been reported rarely, predominantly in the elderly. The hyponatraemia generally reverses on discontinuation of paroxetine.</p><p><strong>Haemorrhage</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_281aa36f-c586-4b21-b4cf-77da2a68fc9a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Skin and mucous membrane bleedings (including gastrointestinal and gynaecological bleeding) have been reported following treatment with paroxetine. Paroxetine should therefore be used with caution in patients concomitantly treated with drugs that give an increased risk for bleeding, and in patients with a known tendency for bleeding or those with predisposing conditions (<em>see Adverse Reactions</em>). SSRIs may increase the risk of postpartum haemorrhage (<em>see Pregnancy and Lactation</em>).</p><p><strong>Cardiac Conditions</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_7096d699-1748-4b7b-8497-142d7df39843
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The usual precautions should be observed in patients with cardiac conditions.</p><p><strong>QT Prolongation</strong></p><p>Cases of QT interval prolongation have been reported, although causality with paroxetine has not been established.</p><p>Seroxat CR should be used with caution in patients with a history of QT interval prolongation, patients taking anti-arrhythmic or other medications that may potentially prolong QT interval, or those with relevant pre-existing cardiac disease.</p><p>For further information, <em>see Contraindications and Interactions</em>.</p><p><strong>Symptoms seen on discontinuation of <em>SEROXAT</em> treatment in adults:</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_9d14ef62-81e0-461a-8fbe-e362dffe4633 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>In clinical trials in adults, adverse events seen on treatment discontinuation occurred in 30% of patients treated with <em>SEROXAT</em> compared to 20% of patients treated with placebo. The occurrence of discontinuation symptoms is not the same as the drug being addictive or dependence producing as with a substance of abuse.&nbsp;</p><p>Dizziness, sensory disturbances (including paraesthesia, electric shock sensations and tinnitus), sleep disturbances (including intense dreams), agitation or anxiety, nausea, tremor, confusion, sweating, headache, diarrhoea have been reported.&nbsp; Generally, these symptoms are mild to moderate, however, in some patients they may be severe in intensity.&nbsp; They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.&nbsp; Generally, these symptoms are self-limiting and usually resolve within two weeks, though in some individuals they may be prolonged (two to three months or more).&nbsp; It is therefore advised that <em>SEROXAT</em> should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (<em>see &quot;Discontinuation of SEROXAT&quot;, Dosage and Administration</em>).</p><p><strong>Sexual dysfunction</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_2f7dd1de-6a3e-4da9-ae4f-2fd232bb942f
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>SSRIs may cause symptoms of sexual dysfunction (see Adverse Reactions). There have been reports of long-lasting sexual dysfunction where the symptoms have continued despite discontinuation of SSRIs.<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_3cc68b1b-fa6c-4bdf-b22d-64084ea42701 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Symptoms seen on discontinuation of <em>SEROXAT</em> treatment in children and adolescents:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_3739059b-286a-4742-bafc-e9058119b6c6
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>In clinical trials in children and adolescents, adverse events seen on treatment discontinuation occurred in 32% of patients treated with <em>SEROXAT </em>compared to 24% of patients treated with placebo.&nbsp; Events reported upon discontinuation of <em>SEROXAT</em> at a frequency of at least 2% of patients and which occurred at a rate at least twice that of placebo were: emotional lability (including suicidal ideation, suicide attempt, mood changes and tearfulness), nervousness, dizziness, nausea and abdominal pain (<em>see Adverse Reactions</em>).</p><p><strong><em>SEROXAT </em></strong><strong>CR 12.5&nbsp;mg tablets only</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_1642c828-c5eb-467d-9429-6ddeaaefc834
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;mso-bidi-font-size:
10.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-ansi-language:EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p>The paroxetine 12.5&nbsp;mg controlled release tablet coating (Opadry Yellow: YS-1-2007) contains the colouring agent Sunset Yellow Lake (FD&amp;C Yellow No.&nbsp;6 aluminium lake), an azo dye which may cause allergic-type reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Serotonergic drugs </strong></p><p>As with other SSRIs, co-administration with serotonergic drugs may lead to an incidence of 5‑HT associated effects (serotonin syndrome: <em>see Warnings and Precautions</em>).&nbsp; Caution should be advised, and a closer clinical monitoring is required when serotonergic drugs (such as L‑tryptophan, triptans, tramadol, SSRIs, lithium, fentanyl and St. John&#39;s Wort &ndash; <em>Hypericum perforatum</em> &ndash; preparations)<strong><em> </em></strong>are combined with <em>SEROXAT</em> CR.&nbsp;</p><p>Concomitant use of <em>SEROXAT</em> CR and MAO inhibitors (including linezolid, an antibiotic which is a reversible non‑selective MAO inhibitor and methylthioninium chloride (methylene blue)) is contraindicated (<em>see Contraindications</em>).</p><p><strong>Pimozide</strong></p><p>Increased pimozide levels have been demonstrated in a study of a single low dose pimozide (2&nbsp;mg) when co‑administered with paroxetine.&nbsp; This is explained by the known CYP2D6 inhibitory properties of paroxetine.&nbsp; Due to the narrow therapeutic index of pimozide and its known ability to prolong QT&nbsp;interval, concomitant use of pimozide and <em>SEROXAT </em>CR tablets is contraindicated (<em>see Contraindications</em>).</p><p><strong>Drug metabolising enzymes </strong></p><p>The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug metabolising enzymes.</p><p>When paroxetine is to be co-administered with a known drug metabolising enzyme inhibitor, consideration should be given to using doses at the lower end of the range.</p><p>No initial dosage adjustment is considered necessary when the drug is to be co‑administered with known drug metabolising enzyme inducers (e.g. carbamazepine, rifampicin, phenobarbital,<strong><em> </em></strong>phenytoin).&nbsp; Any subsequent dosage adjustment should be guided by clinical effect (tolerability and efficacy).</p><p><em>Fosamprenavir/ritonavir:</em> Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).</p><p><em>Procyclidine:</em>&nbsp; Daily administration of paroxetine increases significantly the plasma levels of procyclidine.&nbsp; If anti-cholinergic effects are seen, the dose of procyclidine should be reduced.</p><p><em>Anticonvulsants:</em>&nbsp; carbamazepine, phenytoin, sodium valproate.&nbsp; Concomitant administration does not seem to show any effect on pharmacokinetic/dynamic profile in epileptic patients.</p><p>&nbsp;</p><p><strong>Neuromuscular Blockers</strong></p><p>SSRIs may reduce plasma cholinesterase activity resulting in a prolongation of the neuromuscular blocking action of mivacurium and suxamethonium.</p><p><strong>CYP2D6 inhibitory potency of paroxetine</strong></p><p>As with other antidepressants, including other SSRIs, paroxetine inhibits the hepatic cytochrome P450 enzyme CYP2D6.&nbsp; Inhibition of CYP2D6 may lead to increased plasma concentrations of co-administered drugs metabolised by this enzyme.&nbsp; These include certain tricyclic antidepressants (e.g. amitriptyline, nortriptyline, imipramine and desipramine), phenothiazine neuroleptics (e.g. perphenazine and thioridazine, <em>see Contraindications</em>), risperidone, atomoxetine, certain Type 1c antiarrhythmics (e.g. propafenone and flecainide) and metoprolol.</p><p>Tamoxifen has an important active metabolite, endoxifen, which is produced by CYP2D6 and contributes significantly to the efficacy of tamoxifen.&nbsp; Irreversible inhibition of CYP2D6 by paroxetine leads to reduced plasma concentrations of endoxifen (<em>see Warnings and Precautions).</em></p><p><strong>CYP3A4</strong></p><p>An <em>in vivo</em> interaction study involving the co-administration under steady state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. A similar <em>in vivo</em> interaction study revealed no effect of paroxetine on alprazolam pharmacokinetics and vice-versa. Concurrent administration of paroxetine with terfenadine, alprazolam and other drugs that are CYP3A4 substrates would not be expected to cause a hazard.</p><p>Clinical studies have shown the absorption and pharmacokinetics of paroxetine to be unaffected or only marginally affected (i.e. at a level which warrants no change in dosing regimen) by:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>food </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antacids </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>digoxin </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>propranolol </strong></p><p><strong>alcohol:</strong> paroxetine does not increase the impairment of mental and motor skills caused by alcohol, however, the concomitant use of <em>SEROXAT </em>and alcohol is not advised</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Fertility</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span lang=EN-US style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-ascii-theme-font:major-bidi;mso-fareast-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d98bb780-b63a-456d-9bb0-1afc8198b3be \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-fareast-font-family:
"Times New Roman";mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi;
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Some clinical studies have shown that SSRIs (including <em>SEROXAT</em>) may affect sperm quality. This effect appears to be reversible following discontinuation of treatment. Changes in sperm quality may affect fertility in some men.</p><p><strong>Pregnancy</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b3f15b72-0f12-4eba-95ab-e6708b53317b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Animal studies have not shown any teratogenic or selective embryotoxic effects.</p><p>Epidemiological studies of pregnancy outcomes following maternal exposure to antidepressants in the first trimester have reported an increase in the risk of congenital malformations, particularly cardiovascular (e.g. ventricular and atrial septal defects), associated with the use of paroxetine.&nbsp; The data suggest that the risk of having an infant with a cardiovascular defect following maternal paroxetine exposure is approximately&nbsp;1/50, compared with an expected rate for such defects of approximately&nbsp;1/100 infants in the general population.</p><p>The prescribing physician will need to weigh the option of alternative treatments in women who are pregnant or are planning to become pregnant, and should only prescribe <em>SEROXAT </em>CR if the potential benefit outweighs the potential risk.&nbsp; If a decision is taken to discontinue <em>SEROXAT </em>CR treatment in a pregnant woman, the prescriber should consult <em>Dosage and Administration - Discontinuation of SEROXAT</em> and <em>Warnings and Precautions &ndash; Symptoms seen on discontinuation of SEROXAT treatment in adults</em>.</p><p>There have been reports of premature birth in pregnant women exposed to paroxetine or other SSRIs, although a causal relationship with drug therapy has not been established.</p><p>Observational data have provided evidence of an increased risk (less than two-fold) of postpartum haemorrhage following exposure to SSRIs within one month prior to birth.</p><p>Neonates should be observed if maternal use of <em>SEROXAT </em>continues into the later stages of pregnancy, because there have been reports of complications in neonates exposed to <em>SEROXAT</em> or other SSRIs late in the third trimester of pregnancy.&nbsp; However, a causal association with drug therapy has not been confirmed.&nbsp; Reported clinical findings have included: respiratory distress, cyanosis, apnoea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycaemia, hypertonia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, lethargy, constant crying and somnolence. In some instances the reported symptoms were described as neonatal withdrawal symptoms. In a majority of instances the complications were reported to have arisen either immediately or soon (&lt;24&nbsp;hours) after delivery.</p><p>Epidemiological studies have shown that the use of SSRIs (including paroxetine) in pregnancy, particularly use in late pregnancy, was associated with an increased risk of persistent pulmonary hypertension of the newborn (PPHN).&nbsp; The increased risk among infants born to women who used SSRIs late in pregnancy was reported to be four to five times higher than observed in the general population (rate of 1 to 2 per1000&nbsp;pregnancies).</p><p><strong>Lactation</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b3b75a45-0446-4625-9348-e30e91e89cdb \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:12.0pt;
font-family:"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";
mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Small amounts of paroxetine are excreted into breast milk.&nbsp; In published studies, serum concentrations in breast-fed infants were undetectable (&lt;2&nbsp;nanograms/mL) or very low (&lt;4&nbsp;nanograms/mL).&nbsp; No signs of drug effects were observed in these infants.&nbsp; Nevertheless, <em>SEROXAT </em>should not be used during lactation unless the expected benefits to the mother justify the potential risks for the infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical experience has shown that therapy with <em>SEROXAT </em>is not associated with impairment of cognitive or psychomotor function. However, as with all psychoactive drugs, patients should be cautioned about their ability to drive a car and operate machinery.</p><p>Although paroxetine does not increase the mental and motor skill impairments caused by alcohol, the concomitant use of <em>SEROXAT </em>CR and alcohol is not advised.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some of the adverse experiences listed below may decrease in intensity and frequency with continued treatment and do not generally lead to cessation of therapy.</p><p>Adverse drug reactions are listed below by system organ class and frequency.&nbsp; Frequencies are defined as very common (&sup3;1/10), common (&sup3;1/100, &lt;1/10), uncommon (&sup3;1/1,000, &lt;1/100), rare (&sup3;1/10,000, &lt;1/1,000), very rare (&lt;1/10,000), including isolated reports.&nbsp; Common and uncommon events were generally determined from pooled safety data from a clinical trial population of &gt;8000 paroxetine-treated patients and are quoted as excess incidence over placebo.&nbsp; Rare and very rare events were generally determined from post-marketing data and refer to reporting rate rather than true frequency.</p><p><strong>Blood &amp; lymphatic system disorders</strong><br />Uncommon: abnormal bleeding, predominantly of the skin and mucous membranes (including ecchymosis and gynaecological bleeding).<br />Very rare: thrombocytopenia.</p><p>Unknown: Leukopenia</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Immune system disorders</strong><br />Very rare: severe allergic reactions (including anaphylactoid reactions and angioedema).</p><p><strong>Endocrine disorders</strong><br />Very rare: syndrome of inappropriate anti-diuretic hormone secretion (SIADH).</p><p><strong>Metabolism &amp; nutrition disorders</strong><br />Common: increases in cholesterol levels, decreased appetite.<br />Rare: hyponatraemia.</p><p>Hyponatraemia has been reported predominantly in elderly patients and is sometimes due to syndrome of inappropriate anti-diuretic hormone secretion (SIADH).</p><p>&nbsp;</p><p><strong>Psychiatric disorders</strong><br />Common: somnolence, insomnia, agitation, abnormal dreams (including nightmares).<br />Uncommon: confusion, hallucinations.<br />Rare: manic reactions.</p><p>These symptoms may be due to the underlying disease.</p><p><strong>Nervous system disorders</strong><br />Common: dizziness, tremor, headache.<br />Uncommon: extrapyramidal disorders.<br />Rare: convulsions, akathisia, restless legs syndrome (RLS).<br />Very rare: serotonin syndrome (symptoms may include agitation, confusion, diaphoresis, hallucinations, hyperreflexia, myoclonus, shivering tachycardia and tremor).</p><p>Reports of extrapyramidal disorders including oro-facial dystonia have been received in patients sometimes with underlying movement disorders or who were using neuroleptic medication.</p><p><strong>Eye disorders</strong><br />Common: blurred vision.<br />Uncommon: mydriasis (<em>see Warnings and Precautions</em>).<br />Very rare: acute glaucoma.</p><p><strong>Cardiac disorders</strong><br />Uncommon: sinus tachycardia.</p><p><strong>Vascular disorders</strong><br />Uncommon: postural hypotension.</p><p><strong>Respiratory, thoracic and mediastinal disorders</strong><br />Common: yawning.</p><p><strong>Gastrointestinal disorders</strong><br />Very common: nausea.<br />Common: constipation, diarrhoea, vomiting, dry mouth.<br />Very rare: gastrointestinal bleeding.</p><p><strong>Hepatobiliary disorders</strong><br />Rare: elevation of hepatic enzymes.<br />Very rare: hepatic events (such as hepatitis, sometimes associated with jaundice and/or liver failure).</p><p>Elevation of hepatic enzymes has been reported.&nbsp; Post-marketing reports of hepatic events (such as hepatitis, sometimes associated with jaundice, and/or liver failure) have also been received very rarely. Discontinuation of paroxetine should be considered if there is prolonged elevation of liver function test results.</p><p>&nbsp;</p><p><strong>Skin &amp; subcutaneous tissue disorders</strong><br />Common: sweating.<br />Uncommon: skin rashes.<br />Very rare: severe cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis), urticaria, photosensitivity reactions.</p><p><strong>Renal &amp; urinary disorders</strong><br />Uncommon: urinary retention, urinary incontinence.</p><p><strong>Reproductive system &amp; breast disorders</strong><br />Very common: sexual dysfunction.<br />Rare: hyperprolactinaemia/galactorrhoea, menstrual disorders (including menorrhagia, metrorrhagia and amenorrhoea).</p><p><strong>General disorders &amp; administration site conditions</strong><br />Common: asthenia, body weight gain.<br />Very rare: peripheral oedema.</p><p><strong>Symptoms seen on discontinuation of paroxetine treatment:</strong><br />Common: dizziness, sensory disturbances, sleep disturbances, anxiety, headache.<br />Uncommon: agitation, nausea, tremor, confusion, sweating, diarrhoea.</p><p>As with many psychoactive medicines, discontinuation of <em>SEROXAT </em><em>(</em>particularly when abrupt) may lead to symptoms such as dizziness, sensory disturbances (including paraesthesia, electric shock sensations and tinnitus), sleep disturbances (including intense dreams), agitation or anxiety, nausea, headache, tremor, confusion, diarrhoea and sweating. In the majority of patients, these events are mild to moderate and are self-limiting. No particular patient group appears to be at higher risk of these symptoms; it is therefore advised that when paroxetine treatment is no longer required, gradual discontinuation by dose tapering be carried out (<em>see Dosage and Administration and Warnings and Precautions</em>).</p><p><strong>Adverse Events from Paediatric Clinical Trials</strong></p><p>In paediatric clinical trials the following adverse events, were reported at a frequency of at least 2% of patients and occurred at a rate at least twice that of placebo: emotional lability (including self-harm, suicidal thoughts, attempted suicide, crying and mood fluctuations), hostility, decreased appetite, tremor, sweating, hyperkinesia and agitation.&nbsp; Suicidal thoughts and suicide attempts were mainly observed in clinical trials of adolescents with Major Depressive Disorder. Hostility occurred particularly in children with obsessive compulsive disorder, and especially in younger children less than 12 years of age).</p><p>In studies that used a tapering regimen (daily dose decreased by 10&nbsp;mg/day at weekly intervals to a dose of 10&nbsp;mg/day for one week), symptoms reported during the taper phase or upon discontinuation of <em>SEROXAT </em>at a frequency of at least 2% of patients and occurred at a rate at least twice that of placebo were: emotional lability, nervousness, dizziness, nausea and abdominal pain (<em>see Warnings and Precautions</em>).</p><p><strong>To report any side effect(s):</strong></p><p><strong>Kingdom of Saudi Arabia</strong></p><p><strong>-</strong><strong>National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa&nbsp;</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: <u>s</u>audi.safety@gsk.com<u>&nbsp; </u></li><li>Website: https://gskpro.com/en-sa/<u> </u></li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Symptoms and Signs</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:
EN-GB'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_536eb08d-6640-4ace-a797-14617d6171ef \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>A wide margin of safety is evident from available overdose information on <em>SEROXAT.</em></p><p>Experience of <em>SEROXAT </em>in overdose has indicated that, in addition to those symptoms mentioned under Adverse Reactions, fever, blood pressure changes, involuntary muscle contractions, anxiety and tachycardia have been reported.</p><p>Patients have generally recovered without serious sequelae even when doses of up to 2000&nbsp;mg have been taken alone. Events such as coma or ECG changes have occasionally been reported and, very rarely a fatal outcome, but generally when <em>SEROXAT </em>was taken in conjunction with other psychotropic drugs with or without alcohol.</p><p><strong>Treatment</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:12.0pt;font-family:"Times New Roman",serif;
mso-fareast-font-family:"Times New Roman";mso-ansi-language:EN-GB;layout-grid-mode:
line'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8a85b636-3cfa-482a-b821-e46a2bd2d5ff \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>No specific antidote is known.</p><p>The treatment should consist of those general measures employed in the management of overdose with any antidepressant.&nbsp; Supportive care with frequent monitoring of vital signs and careful observation is indicated. Patient management should be as clinically indicated, or as recommended by the national poisons centre, where available.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ATC Code</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_52870a5d-6ff8-4ca0-abc5-2292530ae56f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Anatomical Therapeutic Chemical (ATC) code: N06A B05.</p><p>Pharmacotherapeutic&nbsp;group:&nbsp;Antidepressants &ndash; selective serotonin reuptake inhibitors.</p><p><strong>Mechanism of Action</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2556abda-859e-4b4e-99c4-a6a78341b01f \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Paroxetine is a potent and selective inhibitor of serotonin (5-hydroxytryptamine, 5-HT) re-uptake and its antidepressant action and efficacy in the treatment of OCD and panic disorder is thought to be related to its specific inhibition of serotonin re-uptake in brain neurones.</p><p>Paroxetine is chemically unrelated to the tricyclic, tetracyclic and other available antidepressants.</p><p>Paroxetine has low affinity for muscarinic cholinergic receptors and animal studies have indicated only weak anticholinergic properties.</p><p>In accordance with this selective action, <em>in vitro</em> studies have indicated that, in contrast to tricyclic antidepressants, paroxetine has little affinity for alpha<sub>1</sub>, alpha<sub>2</sub> and beta-adrenoceptors, dopamine (D2), 5-HT<sub>1</sub> like, 5-HT<sub>2</sub> and histamine (H<sub>1</sub>) receptors. This lack of interaction with post-synaptic receptors <em>in vitro</em> is substantiated by <em>in vivo</em> studies which demonstrate lack of CNS depressant and hypotensive properties.</p><p><strong>Pharmacodynamic Effects</strong><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-fareast-font-family:
"Times New Roman";mso-ansi-language:EN-GB;mso-fareast-language:EN-GB;
mso-bidi-font-style:italic'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_09d86963-d5e6-48af-bdfe-e841f6e37f8a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Paroxetine does not impair psychomotor function and does not potentiate the depressant effects of ethanol.</p><p>As with other selective 5-HT uptake inhibitors, paroxetine causes symptoms of excessive 5-HT receptor stimulation when administered to animals previously given monoamine oxidase (MAO) inhibitors or tryptophan.</p><p>Behavioural and EEG studies indicate that paroxetine is weakly activating at doses generally above those required to inhibit 5-HT uptake. The activating properties are not &quot;amphetamine-like&quot; in nature.</p><p>Animal studies indicate that paroxetine is well tolerated by the cardiovascular system.</p><p>Paroxetine produces no clinically significant changes in blood pressure, heart rate and ECG after administration to healthy subjects.</p><p>Studies indicate that, in contrast to antidepressants which inhibit the uptake of nor-adrenaline, paroxetine has a much-reduced propensity to inhibit the antihypertensive effects of guanethidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_ddff62a1-a4eb-4812-a49c-9d62a01411e5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Paroxetine is well absorbed after oral dosing and undergoes first-pass metabolism. <em>SEROXAT</em> CR tablets control the dissolution rate of paroxetine over a period of four to five hours. In addition to controlling the rate of drug release <em>in vivo</em>, an enteric coat delays the start of drug release until <em>SEROXAT</em> CR tablets have left the stomach. Compared to immediate release formulations of paroxetine, controlled release tablets have a reduced absorption rate.</p><p>Due to first-pass metabolism, the amount of paroxetine available to the systemic circulation is less than that absorbed from the gastrointestinal tract.</p><p>Steady state systemic levels are attained by 7 to 14 days after starting treatment with immediate or controlled release formulations and pharmacokinetics do not appear to change during long-term therapy.</p><p><strong>Distribution</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b577b387-8a15-41b2-a4d1-c8d4ee1b2675 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Paroxetine is extensively distributed into tissues and pharmacokinetic calculations indicate that only 1% of the paroxetine in the body resides in the plasma.</p><p>Approximately 95% of the paroxetine present in the plasma is protein bound at therapeutic concentrations.</p><p>No correlation has been found between paroxetine plasma concentrations and clinical effect (adverse experiences and efficacy).</p><p><strong>Metabolism</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_eadb0b97-3899-44f9-8b1b-e5c75304b6f3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>The principal metabolites of paroxetine are polar and conjugated products of oxidation and methylation, which are readily cleared. In view of their relative lack of pharmacological activity, it is most unlikely that they contribute to the therapeutic effects of paroxetine.</p><p>Metabolism does not compromise paroxetine&#39;s selective action on neuronal 5-HT uptake.</p><p><strong>Elimination</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_eede00bd-a99e-413b-9304-fb98493da9a1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Urinary excretion of unchanged paroxetine is generally less than 2% of dose whilst that of metabolites is about 64% of dose. About 36% of the dose is excreted in faeces, probably via the bile, of which unchanged paroxetine represents less than 1% of the dose. Thus paroxetine is eliminated almost entirely by metabolism.</p><p>Metabolite excretion is biphasic, being initially a result of first-pass metabolism and subsequently controlled by systemic elimination of paroxetine.</p><p>The elimination half-life is variable but is generally about one day.</p><p><strong>Special Patient Populations</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_626c447b-d37d-447c-b77f-f0e8f874c9d3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB;mso-bidi-font-style:italic'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elderly and Renal/Hepatic Impairment</strong></p><p>Increased plasma concentrations of paroxetine occur in elderly subjects, in subjects with severe renal and in those with hepatic impairment, but the range of plasma concentrations overlaps that of healthy adult subjects.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.3.Pre-Clinical Safety Data</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e8d716a1-2a3c-4f9b-aa8f-7e219498b1ac \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:12.0pt;font-family:
"Times New Roman",serif;mso-fareast-font-family:"Times New Roman";mso-ansi-language:
EN-GB;mso-fareast-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Toxicology studies have been conducted in rhesus monkeys and albino rats; in both, the metabolic pathway is similar to that described for humans.&nbsp; As expected with lipophilic amines, including tricyclic antidepressants, phospholipidosis was detected in rats.&nbsp; Phospholipidosis was not observed in primate studies of up to one year duration at doses that were six times higher than the recommended range of clinical doses.</p><p>Carcinogenesis:&nbsp; In two-year studies conducted in mice and rats, paroxetine had no tumorigenic effect.</p><p>Genotoxicity:&nbsp; Genotoxicity was not observed in a battery of <em>in vitro</em> and <em>in vivo</em> tests.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core:</em> Hypromellose; Povidone; Lactose Monohydrate; Magnesium Stearate; Colloidal silicon dioxide; Glyceryl Dibehenate and the following colourants: Yellow Ferric Oxide (12.5&nbsp;mg tablets) and Red Ferric Oxide (25&nbsp;mg tablets).</p><p><em>Tablet coating: </em>&nbsp;Methacrylic Acid and Ethyl Acrylate Copolymer Dispersion; Talc; Triethyl citrate, Opadry Yellow, 15B120039 (12.5&nbsp;mg tablets, includes the colouring agent Sunset Yellow Lake (FD&amp;C Yellow No.&nbsp;6 aluminium lake)), Opadry Pink, Y-1-1262 (25&nbsp;mg tablets). For important information about some of these excipients <em>see Warnings &amp; Precautions</em>.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known incompatibilities with <em>SEROXAT</em><strong> </strong>CR tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Foil blister packs or HDPE bottles with child-resistant closures.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seroxat CR is a Hazardous drug, as it may cause developmental toxicity and reproductive toxicity.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The tablets should not be divided, broken or crushed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant caregivers and healthcare providers should avoid exposure to Seroxat CR tablets.</p><p>Not all packs are marketed in every country</p><p><strong><em>SEROXAT</em></strong><strong> </strong>is a trademark owned by or licensed to GSK group of companies.</p><p>&copy; 2024 GSK group of companies. All rights reserved</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Bora Pharmaceuticals Service Inc., Mississauga, Canada
Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS49/IPI28 
Date of issue: 16 July 2024

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>